Resonant (RESN) 10-K 14 Mar 19 2018 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Mar. 12, 2019	Jun. 30, 2018
Document and Entity Information
Entity Registrant Name	Resonant Inc
Entity Central Index Key	0001579910
Document Type	10-K
Document Period End Date	Dec. 31, 2018
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 103
Entity Common Stock, Shares Outstanding		27,728,387
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	FY

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2018	Dec. 31, 2017
CURRENT ASSETS
Cash and cash equivalents	$ 4,394,000	$ 19,524,000
Investments held-to-maturity	16,863,000	0
Accounts receivable	165,000	50,000
Prepaid expenses and other current assets	364,000	536,000
Restricted cash	0	100,000
TOTAL CURRENT ASSETS	21,786,000	20,210,000
PROPERTY AND EQUIPMENT
Property and equipment	3,784,000	3,212,000
Less: Accumulated depreciation and amortization	(1,797,000)	(1,858,000)
PROPERTY AND EQUIPMENT, NET	1,987,000	1,354,000
NONCURRENT ASSETS
Intangible assets, net	1,374,000	1,353,000
Restricted cash	211,000	0
Goodwill	817,000	824,000
Other assets	69,000	19,000
TOTAL NONCURRENT ASSETS	2,471,000	2,196,000
TOTAL ASSETS	26,244,000	23,760,000
CURRENT LIABILITIES
Accounts payable	695,000	708,000
Accrued expenses	464,000	314,000
Accrued salaries and payroll related expenses	1,835,000	1,936,000
Deferred revenue	271,000	143,000
TOTAL CURRENT LIABILITIES	3,265,000	3,101,000
LONG-TERM LIABILITIES
Deferred rent	81,000	10,000
Deferred income taxes	0	1,000
TOTAL LIABILITIES	3,346,000	3,112,000
Commitments and contingencies (Note 10)
STOCKHOLDERS’ EQUITY
Common stock, $0.001 par value, 47,000,000 authorized and 19,511,276 outstanding as of December 31, 2017 and 27,391,290 outstanding as of December 31, 2018	27,000	20,000
Preferred stock, $0.001 par value, 3,000,000 shares authorized and none outstanding as of December 31, 2017 and December 31, 2018	0	0
Additional paid-in capital	115,450,000	88,447,000
Accumulated other comprehensive loss	(15,000)	(7,000)
Accumulated deficit	(92,564,000)	(67,812,000)
TOTAL STOCKHOLDERS’ EQUITY	22,898,000	20,648,000
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 26,244,000	$ 23,760,000

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2018	Dec. 31, 2017
Statement of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	47,000,000	47,000,000
Common stock, shares outstanding (in shares)	27,391,290	19,511,276
Common stock, shares, issued (in shares)	27,391,290	19,511,276
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	3,000,000	3,000,000
Preferred stock, shares outstanding (in shares)	0	0

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Income Statement [Abstract]
REVENUES	$ 524,000	$ 653,000
OPERATING EXPENSES
Research and development	14,271,000	10,045,000
Sales, marketing and administration	11,546,000	9,644,000
TOTAL OPERATING EXPENSES	25,817,000	19,689,000
NET OPERATING LOSS	(25,293,000)	(19,036,000)
OTHER INCOME (EXPENSE)
Interest and investment income	481,000	67,000
Warrant inducement expense	0	(2,688,000)
Other expense	(3,000)	(10,000)
TOTAL OTHER INCOME (EXPENSE)	478,000	(2,631,000)
LOSS BEFORE INCOME TAXES	(24,815,000)	(21,667,000)
Provision for (benefit from) income taxes	(1,000)	14,000
NET LOSS	(24,816,000)	(21,653,000)
Foreign currency translation adjustment, net of tax	(8,000)	44,000
COMPREHENSIVE LOSS	$ (24,824,000)	$ (21,609,000)
NET LOSS PER SHARE - BASIC AND DILUTED (in dollars per share)	$ (0.98)	$ (1.44)
Weighted average shares outstanding — basic and diluted (shares)	25,290,426	15,015,446

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($)	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss
Balance (in shares) at Dec. 31, 2016		12,468,647
Balance at Dec. 31, 2016	$ 10,133,000	$ 12,000	$ 56,331,000	$ (46,159,000)	$ (51,000)
Increase (Decrease) in Stockholders' Equity
Issuance of common stock for compensation (in shares)		649,359
Issuance of common stock for compensation		$ 1,000	(1,000)
Stock-based compensation	4,136,000		4,136,000
Sales of common stock, net of offering costs (in shares)		3,603,817
Sale of common stock, net of offering costs	15,950,000	$ 4,000	15,946,000
Exercise of warrants, cashless (in shares)		147,847
Exercise of warrants for cash (in shares)		2,608,678
Common stock issued in exchange for warrants	11,960,000	$ 3,000	11,957,000
Exercise of stock options, cashless (in shares)		3,758
Exercise of warrants for cash (in shares)		29,170
Exercises of warrants	78,000		78,000
Net loss	(21,653,000)
Foreign currency translation adjustment, net of tax	$ 44,000				44,000
Balance (in shares) at Dec. 31, 2017	19,511,276	19,511,276
Balance at Dec. 31, 2017	$ 20,648,000	$ 20,000	88,447,000	(67,812,000)	(7,000)
Increase (Decrease) in Stockholders' Equity
Issuance of common stock for compensation (in shares)		1,051,939
Issuance of common stock for compensation	1,000	$ 1,000
Stock-based compensation	5,698,000		5,698,000
Sales of common stock, net of offering costs (in shares)		6,571,428
Sale of common stock, net of offering costs	21,189,000	$ 6,000	21,183,000
Exercise of warrants for cash (in shares)		89,142
Common stock issued in exchange for warrants	$ 260,000		260,000
Exercise of stock options, cashless (in shares)		242,913
Exercise of warrants for cash (in shares)	4,692	4,692
Exercises of warrants	$ 14,000		14,000
Repurchase and retirement of common stock	(152,000)		(152,000)
Net loss	(24,816,000)			(24,816,000)
Foreign currency translation adjustment, net of tax	$ (8,000)				(8,000)
Balance (in shares) at Dec. 31, 2018	27,391,290	27,391,290
Balance at Dec. 31, 2018	$ 22,898,000	$ 27,000	$ 115,450,000	$ (92,564,000)	$ (15,000)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (24,816,000)	$ (21,653,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	840,000	721,000
Stock-based compensation	5,262,000	4,121,000
Non-cash warrant inducement expense	0	2,688,000
Non-cash interest and investment income	(153,000)	0
Non-cash patent write-off	96,000	0
(Gain) loss on sale of property and equipment	(7,000)	2,000
Changes in assets and liabilities:
Accounts receivable	(115,000)	6,000
Prepaids and other current assets	239,000	(376,000)
Other assets	(50,000)	(3,000)
Deferred taxes	(1,000)	(14,000)
Accounts payable	107,000	(143,000)
Accrued expenses	(66,000)	163,000
Accrued salaries and payroll related expenses	334,000	208,000
Deferred revenue	128,000	(184,000)
Deferred rent	71,000	(10,000)
Net cash used in operating activities	(18,131,000)	(14,474,000)
CASH FLOWS FROM INVESTING ACTIVITIES
Proceeds from sale of property and equipment	16,000	7,000
Purchases of property and equipment	(1,285,000)	(815,000)
Expenditures for patents and domain names	(219,000)	(332,000)
Redemptions of investments held-to-maturity	39,590,000	4,747,000
Purchases of investments held-to-maturity	(56,300,000)	0
Net cash provided by (used in) investing activities	(18,198,000)	3,607,000
CASH FLOWS FROM FINANCING ACTIVITIES
Net proceeds from the sale of common stock from private placement offerings	0	15,950,000
Net proceeds from the sale of common stock from underwritten public offering	21,190,000	0
Acquisition of common stock under Repurchase Program	(152,000)	0
Proceeds from exercises of warrants	260,000	9,272,000
Proceeds from exercises of stock options	14,000	78,000
Net cash provided by financing activities	21,312,000	25,300,000
Effects of currency translation on cash, cash equivalents and restricted cash	(2,000)	7,000
NET INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH	(15,019,000)	14,440,000
CASH, CASH EQUIVALENTS AND RESTRICTED CASH — Beginning of year	19,624,000	5,184,000
CASH, CASH EQUIVALENTS AND RESTRICTED CASH — End of year	4,605,000	19,624,000
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Cash paid for taxes	3,000	1,000
SUPPLEMENTAL DISCLOSURE OF NON-CASH ACTIVITIES
Common stock issued in settlement of accrued salaries and payroll related expenses	436,000	119,000
Stock options issued in settlement of liability	0	332,000
Property and equipment included in accounts payable	95,000	245,000
Property and equipment included in accrued liabilities	305,000	95,000
Noncash or Part Noncash Acquisition, Intangible Assets Acquired	39,000	9,000
Patents included in accounts payable	6,000	0
Total cash, cash equivalents and restricted cash	$ 19,624,000	$ 5,184,000

ORGANIZATION AND DESCRIPTION OF

ORGANIZATION AND DESCRIPTION OF BUSINESS	12 Months Ended
	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
ORGANIZATION AND DESCRIPTION OF BUSINESS	ORGANIZATION AND DESCRIPTION OF BUSINESS Overview Resonant Inc. is a late-stage development company located in Goleta, California. We were incorporated in Delaware in January 2012 as a wholly owned subsidiary of Superconductor Technologies Inc., or STI. Resonant LLC, a limited liability company, was formed in California in May 2012. We changed our form of ownership from a limited liability company to a corporation in an exchange transaction in June 2013, when we commenced business. We are the successor of Resonant LLC. We completed our initial public offering, or IPO, on May 29, 2014. On July 6, 2016 we acquired all of the issued and outstanding capital stock of GVR Trade S.A, or GVR. GVR is a wholly owned subsidiary of Resonant Inc. We have created an innovative software, intellectual property, or IP, and services platform that has the ability to increase designer efficiency, reduce the time to market and lower unit costs in the designs of filters for radio frequency, or RF, front-ends for the mobile device industry. The RF front-end, or RFFE, is the circuitry in a mobile device responsible for analog signal processing and is located between the device’s antenna and its digital circuitry. The software platform we continue to develop is based on fundamentally new technology that we call Infinite Synthesized Networks ® , or ISN ® , to configure and connect resonators, the building blocks of RF filters. Filters are a critical component of the RF front-end used to select desired radio frequency signals and reject unwanted signals. We believe licensing our designs is the most direct and effective means of validating our ISN ® platform and related IP libraries. Our target customers make part or all of the RFFE. We intend to retain ownership of our designs, and we expect to be compensated through license fees and royalties based on sales of RFFE filters that incorporate our designs. Capital Resources and Liquidity We are using the net proceeds from the sale of our common stock for product development to commercialize our technology, research and development, the development of our patent strategy and expansion of our patent portfolio, as well as for working capital and other general corporate purposes. We have earned minimal revenues since inception, and our operations have been funded with initial capital contributions and proceeds from the sale of equity securities and debt. At December 31, 2017 and December 31, 2018 , we had incurred accumulated losses totaling $67.8 million and $92.6 million , respectively. The losses are primarily the result of research and development costs associated with commercializing our technology, combined with start-up, financing and public company costs. We expect to continue to incur substantial costs as we continue to engage customers, increase the number of devices under design and build the infrastructure to support our anticipated growth. Our consolidated financial statements account for the continuation of our business as a going concern. We are subject to the risks and uncertainties associated with a new business. Our principal sources of liquidity as of December 31, 2018 consist of existing cash, cash equivalents and investments totaling $21.3 million . During the year ended December 31, 2018 , we used $19.6 million of cash and investments for operating activities, the purchase of property and equipment, and expenditures for patents. Due to these conditions, along with anticipated growth, substantial doubt exists as to our ability to continue as a going concern. After evaluation of these conditions, we believe our current resources, in the absence of material revenues, will provide sufficient funding for planned operations into the second half of 2019. If necessary, we will seek to raise additional capital from the sale of equity securities or the incurrence of indebtedness to allow us to continue operations. There can be no assurance that additional financing will be available to us on acceptable terms, or at all. Additionally, if we issue additional equity securities to raise funds, whether to existing investors or others, the ownership percentage of our existing stockholders would be reduced. New investors may demand rights, preferences or privileges senior to those of existing holders of common stock. Additionally, we may be limited as to the amount of funds we can raise pursuant to SEC rules and the continued listing requirements of NASDAQ. If we cannot raise needed funds, we might be forced to make substantial reductions in our operating expenses, which could adversely affect our ability to implement our business plan and ultimately our viability as a company. These consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might result from this uncertainty. We have a Form S-3 universal shelf registration statement on file with the SEC. The universal shelf registration statement on Form S-3 permits us to sell, in one or more public offerings, shares of our common stock, shares of preferred stock or debt securities, or any combination of such securities and warrants to purchase securities, for proceeds in an aggregate amount of up to $50.0 million, subject to potential limitations on the amount of securities we may sell in any twelve-month period. The Form S-3 will expire in November 2021. No securities have been issued pursuant to the registration statement.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation and Use of Estimates —The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or U.S. GAAP. In the opinion of management, all adjustments (consisting of normal accruals) considered for a fair presentation have been included. Significant estimates made in preparing these financial statements include (a) assumptions to calculate the fair values of financial instruments, warrants and equity instruments and other liabilities and the deferred tax asset valuation allowance and (b) the useful lives for depreciable and amortizable assets. Actual results could differ from those estimates. In the opinion of management, all adjustments, including normal recurring accruals considered necessary for a fair presentation, have been included. Consolidation - The accompanying financial statements include the accounts of the Company and its wholly-owned subsidiary, GVR. All significant intercompany balances and transactions have been eliminated. Cash and Cash Equivalents —We consider all liquid instruments purchased with a maturity of three months or less to be cash equivalents. Concentration of Credit Risk —We maintain bank accounts at one U.S. financial institution. The U.S. bank accounts are insured by the Federal Deposit Insurance Corporation (FDIC) for up to $250,000 per account owner. GVR, our wholly owned Swiss-based subsidiary maintains checking accounts at one major national financial institution. Additionally, we maintain a checking account with a very minimal balance at one bank in South Korea, which is used to fund payroll and rent in South Korea. Management believes we are not exposed to significant credit risk due to the financial position of the depository institutions in which our deposits are held. Restricted Cash —Restricted cash at December 31, 2017 represented cash held within a certificate of deposit with a financial institution. The certificate of deposit served as collateral for our corporate credit card program, which was terminated in 2018. The restriction was lifted upon termination of the program. As of December 31, 2018 our restricted cash balance consists of a $211,000 pledged mutual fund account which is held as collateral against a letter of credit issued in May 2018 in connection with the lease of our corporate headquarters. Effective January 1, 2018, we adopted ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash , which requires that the statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Consequently, restricted cash is included in the beginning and ending cash balances on the statement of cash flows. See also Note 10- Commitments and Contingencies, for further details. Investments —Securities held-to-maturity: Management determines the appropriate classification of debt securities at the time of purchase and reevaluates such designation as of each balance sheet date. Investment/debt securities are classified as held-to-maturity when we have the positive intent and ability to hold the securities to maturity. Held-to-maturity securities are stated at amortized cost, adjusted for amortization of premiums and accretion of discounts to maturity computed under the effective interest method. Such amortization is included in investment income. Interest on securities classified as held-to-maturity is included in interest and investment income. When the fair value of an investment instrument classified as held-to-maturity is less than its amortized cost, management assesses whether or not: (i) we have the intent to sell the instrument or (ii) it is more likely than not that we will be required to sell the instrument before its anticipated recovery. If either of these conditions is met, we must recognize an other-than-temporary impairment for the difference between the instrument’s amortized cost basis and its fair value, and include such amounts in other income (expense). For investment instruments that do not meet the above criteria and are not expected to be recovered at the amortized cost basis, the instrument is considered other-than-temporarily impaired. For these instruments, we separate the total impairment into the credit loss component and the amount of the loss related to other factors. In order to determine the amount of the credit loss, we calculate the recovery value by performing a discounted cash flow analysis based on the current cash flows and future cash flows management expects to recover. The discount rate is the effective interest rate implicit in the underlying instrument. The amount of the total other-than-temporary impairment related to credit loss is recognized in earnings and is included in other income (expense). The amount of the total other-than-temporary impairment related to other factors is recognized in other comprehensive income. For investment instruments that have other-than-temporary impairment recognized through earnings, if through subsequent evaluation there is a significant increase in the cash flow expected, the difference between the amortized cost basis and the cash flows expected to be collected is accreted as interest income. Fair Value of Financial Instruments —We measure certain financial assets and liabilities at fair value based on the exchange price that would be received for an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants. The carrying amounts of our financial instruments, including cash equivalents, restricted cash, investments held-to-maturity, accounts payable, and accrued liabilities, approximate fair value due to their short maturities. Accounts Receivable —Trade accounts receivable are stated net of allowances for doubtful accounts. Management estimates the allowance for doubtful accounts based on review and analysis of specific customer balances that may not be collectible, customer payment history and any other customer-specific information that may impact collectability of the receivable. Accounts are considered for write-off when they become past due and when it is determined that the probability of collection is remote. The was no allowance for doubtful accounts at December 31, 2017 and December 31, 2018. Property and Equipment —Property and equipment consists of leasehold improvements associated with our corporate offices, software purchased during the normal course of business, equipment and office furniture and fixtures, all of which are recorded at cost. Depreciation and amortization is recorded using the straight-line method over the respective useful lives of the assets ranging from three to five years . Leasehold improvements are amortized over the shorter of lease term or useful life. Long-lived assets are reviewed for impairment whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable. Intangible Assets, net —Intangible assets are recorded at cost and amortized over the useful life. In the case of business combinations, intangible assets are recorded at fair value. At December 31, 2017 and December 31, 2018 , intangible assets, net, includes patents, domain name and other intangibles purchased from GVR, including customer relationships, technology and trademark. Intangible assets are reviewed for impairment whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable. In certain cases, patents may expire or are abandoned as we no longer plan to pursue them. In such cases we write off the capitalized patent costs as patent abandonment costs which are included in research and development expenses. Goodwill— At December 31, 2017 and December 31, 2018 , goodwill represents the difference between the price paid to acquire GVR and the fair value of the assets acquired, net of assumed liabilities. We review goodwill for impairment annually and whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable. Revenue Recognition —As of January 1, 2018, we recognize revenue in accordance with Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, Topic 606, Revenue from Contracts with Customers. Revenue is recognized upon the transfer of control of promised goods or services to the customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. Revenue consists primarily of upfront non-refundable fees received in connection with filter design projects with customers and royalties. Our performance obligation is to design a licensable filter in accordance with customer specifications. The license of the completed design is considered part of this performance obligation as the design and licensing of the filter are highly interdependent. We recognize revenue over the course of the design development phase as our customers are able to benefit from our design services as they are provided, primarily by marketing the in-process design to their customers. We recognize revenue from our design services based on efforts expended to date. At the end of each reporting period, we reassess our measure of progress and adjust revenue when appropriate. In most cases, upfront non-refundable payments are recognized over a period of 12 to 18 months. Contracts generally include upfront non-refundable fees, intended to support our initial engineering product development efforts, and may include milestone payments based upon the successful completion of certain deliverables. Milestone payments represent variable consideration, and we use the "most likely amount" approach to determine the amount we ultimately expect to receive. At contract inception, we assess the likelihood of achieving milestones to estimate the total consideration we believe we will receive for our services. Our design service contracts also include a functional license over the completed design, which enables our customer to use our design in products marketed to their customers. We also earn royalties for each product shipped by our customer that incorporates one of our designs. Royalty fees are recorded upon shipment by our customer, and payment is generally due within 30 days. We record the expenses related to these projects in the periods incurred and they are generally included in research and development expense. Research and Development —Costs and expenses that can be clearly identified as research and development are charged to expense as incurred in accordance with ASC Topic 730-10, Research and Development . Operating Leases —We lease office space and research facilities under operating leases. Certain lease agreements contain free or escalating rent payment provisions. We recognize rent expense under such leases on a straight-line basis over the term of the lease. Lease renewal periods are considered on a lease-by-lease basis in determining the lease term. Stock-Based Compensation —We account for employee stock options in accordance with ASC Topic 718, Compensation-Stock Compensation . For stock options issued to employees and directors we use the Black-Scholes option valuation model for estimating fair value at the date of grant. For stock options issued for services rendered by non-employees, we recognize compensation expense in accordance with the requirements of ASC Topic 505-50 , Equity , or ASC 505-50, as amended. Non-employee option grants that do not vest immediately upon grant are recorded as an expense over the vesting period. At the end of each financial reporting period prior to performance, the value of these options, as calculated using the Black-Scholes option valuation model, is determined, and compensation expense recognized or recovered during the period is adjusted accordingly. Since the fair market value of options granted to non-employees is subject to change in the future, the amount of the future compensation expense is subject to adjustment until the common stock options are fully vested. We account for restricted stock units issued to employees at fair value, based on the market price of our stock on the date of grant, net of estimated forfeitures. Compensation expense is recognized for the portion of the award that is ultimately expected to vest over the period during which the recipient renders the required services to the Company generally using the straight-line single option method. The fair value of non-employee restricted stock units awarded are remeasured as the awards vest, and the resulting increase or decrease in fair value, if any, is recognized as an increase or decrease to compensation expense in the period the related services are rendered. In the case of award modifications, we account for the modification in accordance with ASU No. 2017-09, Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting , whereby we recognize the effect of the modification in the period the award is modified. Stock-based compensation expense is included in research and development expenses and sales, marketing and administration expenses. Earnings Per Share, or EPS —EPS is computed in accordance with ASC Topic 260, Earnings per Share , and is calculated using the weighted average number of common shares outstanding during each period. Diluted EPS assumes the conversion, exercise or issuance of all potential common stock equivalents unless the effect is to reduce a loss or increase the income per share. Potential common shares consist of the incremental common shares issuable upon the exercise of stock options (using the treasury stock method), the exercise of warrants (using the if-converted method) and the vesting of restricted stock unit awards. Income Taxes —We account for income taxes in accordance with ASC Topic 740, Income Taxes , or ASC 740, which requires the recognition of deferred tax assets and liabilities for the future consequences of events that have been recognized in our consolidated financial statements or tax returns. The measurement of the deferred items is based on enacted tax laws. In the event the future consequences of differences between financial reporting bases and the tax bases of our assets and liabilities result in a deferred tax asset, ASC 740 requires an evaluation of the probability of being able to realize the future benefits indicated by such asset. A valuation allowance related to a deferred tax asset is recorded when it is more likely than not that some portion or the entire deferred tax asset will not be realized. As part of the process of preparing our consolidated financial statements, we are required to estimate our income tax expense in each of the jurisdictions in which we operate. We also assess temporary differences resulting from differing treatment of items for tax and accounting differences. We record a valuation allowance to reduce the deferred tax assets to the amount of future tax benefit that is more likely than not to be realized. For the period when we were organized as a limited liability company, we were treated as a partnership for federal and state income tax purposes under the entity classification domestic default rules. As of December 31, 2017 and December 31, 2018 , no liability for unrecognized tax benefits was required to be reported. We recognize interest and penalties related to income tax matters in income taxes, and there were none for the years ended December 31, 2017 and December 31, 2018 , respectively. We have filed, or are in the process of filing, tax returns that are subject to audit by the respective tax authorities. Although the ultimate outcome is unknown, we believe that any adjustments that may result from tax return audits are not likely to have a material, adverse effect on our consolidated results of operations, financial position or cash flows. Business Combinations— We record business combinations using the acquisition method of accounting and, accordingly, allocate the fair value of purchase consideration to the assets acquired and liabilities assumed based on their fair values at the acquisition date. The excess of the fair value of the purchase consideration over the fair value of the assets acquired and liabilities assumed is recorded as goodwill. The results of operations of the business acquired are included in our consolidated results of operations beginning on the date of acquisition. Foreign Currency Translation —The Swiss Franc has been determined to be the functional currency for the net assets of our Swiss-based subsidiary. We translate the assets and liabilities to U.S. dollars at each reporting period using exchange rates in effect at the balance sheet date and record the effects of the foreign currency translation in accumulated other comprehensive income (loss) in shareholders' equity. We translate the income and expenses to U.S. dollars at each reporting period using the average exchange rate in effect for the period and record the effects of the foreign currency translation as other comprehensive income (loss) in the consolidated statements of comprehensive loss. Gains and losses resulting from foreign currency transactions are included in net loss in the consolidated statements of comprehensive loss. Recent Accounting Pronouncements Leases— In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) , a comprehensive new leases standard that amends various aspects of existing accounting guidance for leases. It will require recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. The main difference between previous U.S. GAAP and the amended standard is the recognition of lease assets and lease liabilities by lessees on the balance sheet for those leases classified as operating leases under previous U.S. GAAP. The accounting applied by a lessor is largely unchanged from that applied under previous U.S. GAAP. As a result, we will have to recognize a liability to make lease payments (the lease liability) and a right-of-use asset representing our right to use the underlying asset for the lease term on the balance sheet. In July 2018, the FASB issued ASU 2018-10, Codification Improvements to Topic 842, Leases , which provides clarity to certain narrow aspects of the new standard and ASU 2018-11, Leases (Topic 842): Targeted Improvements , which provides an optional transition method for adopting the new leases guidance that eliminates comparative period reporting under the new guidance in the year of adoption. The guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted. We plan to adopt the standard, as well as the practical expedients included therein, utilizing the optional transition method as of January 1, 2019. Therefore, we will not restate comparative periods in our 2019 financial statements. We have reviewed our leases and other agreements in order to determine the effects of the new guidance on our consolidated financial statements. We have determined that we have two facility leases that meet the criteria for recognition of lease assets and lease liabilities on the balance sheet under the new guidance. We are not party to any leases for which we are the lessor. We believe the adoption will cause us to recognize approximately $3.0 million in each, right-of-use assets and lease liabilities, in our consolidated financial statements. Intangibles-Goodwill and Other— In January 2017, the FASB issued ASU No. 2017-04, Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment , which simplifies the accounting for goodwill impairments by eliminating step 2 from the goodwill impairment test. The amended guidance will become effective for us commencing in the first quarter of fiscal 2019. We plan to adopt the standard as of January 1, 2019 and we do not believe there will be any material impact to our consolidated financial statements. Compensation-Stock Compensation— In June 2018, the FASB issued ASU No. 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Non-employee Share-Based Payment Accounting , which intends to align the accounting of share-based payment awards issued to employees and non-employees. This update will be effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2018. Early adoption is permitted. We plan to adopt the standard as of January 1, 2019 and we do not believe there will be any material impact to our consolidated financial statements as we have very few share-based payment arrangements with non-employees.

REVENUE RECOGNITION

REVENUE RECOGNITION	12 Months Ended
	Dec. 31, 2018
Revenue from Contract with Customer [Abstract]
REVENUE RECOGNITION	REVENUE RECOGNITION On January 1, 2018, we adopted ASC Topic 606, Revenue from Contracts with Customers, and all of the related amendments and applied it to all contracts using the modified retrospective method. We recognized the cumulative effect of the initial adoption as an adjustment to the opening balance of retained earnings. Comparative financial information has not been restated and continues to be reported under the accounting standards in effect for those periods. The adoption of the guidance resulted in a change in the accounting for milestone payments. Previously, we recognized revenue upon the achievement of a milestone. Under ASC Topic 606, milestone payments are treated as variable consideration and included in the transaction price for our design services. The cumulative effect of the changes made to our consolidated balance sheet as of January 1, 2018 for the adoption of the new standard was as follows: BALANCE SHEET Balance as of December 31, 2017 Adjustments Due to ASC 606 Balance as of January 1, 2018 ASSETS Prepaid expenses and other current assets $ 536,000 $ 67,000 $ 603,000 LIABILITIES AND STOCKHOLDERS' EQUITY Deferred revenue, current $ 143,000 $ 3,000 $ 146,000 Accumulated deficit $ (67,812,000 ) $ 64,000 $ (67,748,000 ) The following table summarizes the impact of the adoption on our Consolidated Balance Sheet and Consolidated Statement of Comprehensive Loss as of and for the year ended December 31, 2018: BALANCE SHEET As of December 31, 2018 As Reported Balances Without Adoption of ASC 606 Effect of Change Increase/(Decrease) ASSETS Prepaid expenses and other current assets $ 364,000 $ 364,000 $ — LIABILITIES AND STOCKHOLDERS' EQUITY Deferred revenue, current $ 271,000 $ 264,000 $ 7,000 Accumulated deficit $ (92,564,000 ) $ (92,557,000 ) $ (7,000 ) STATEMENT OF COMPREHENSIVE LOSS Year Ended December 31, 2018 As Reported Activity Without Adoption of ASC 606 Effect of Change Increase/(Decrease) Revenue $ 524,000 $ 595,000 $ (71,000 ) Net loss $ (24,816,000 ) $ (24,745,000 ) $ 71,000 Our contracts with customers primarily relate to the design of filters for radio frequency, or RF, front-ends for the mobile device industry. Design service contracts generally include a modest upfront payment for the design services and a license over the completed design. We retain ownership of our designs, and therefore are also compensated for our design services through royalties based on sales of RFFE filters that incorporate our designs. We currently do not manufacture or sell any physical products or operate as a contract design company developing designs for a fee. Except for the royalty fees that are recognized as revenue upon use of one of our designs, we recognize revenue related to our design services over the estimated design development period, based on the level of effort expended, as the services are performed, which in most cases is 12 to 18 months but can vary depending upon the difficulty of the design. Other Judgments and Assumptions - We apply the practical expedients available in ASC 606 to not disclose information about 1) remaining performance obligations that have original expected durations of one year or less and 2) variable consideration that is a sales-based or usage-based royalty. Royalty Revenue - Upon completion of design services, our customers retain a license over the completed design. The license will typically last for a minimum of two years, and in many cases for the life of the design. Royalties are sales-based, and we recognize royalty revenue upon shipment, by our customer, of products that include our licensed design. Contract Assets - Contract assets, other than accounts receivable, consist of unbilled revenue and generally arise when revenue is recognized on a contract whose transaction price includes an estimate of variable consideration from milestone payments. We do not have material amounts of contract assets as we have relatively few contracts, only modest design service fees and a small number of contracts containing milestone payments. Contract asset balances are included in Prepaid expenses and other current assets in our Consolidated Balance Sheet. Contract Liabilities - Our contract liabilities consist of customer deposits and deferred revenue. We classify contract liabilities as current or noncurrent based on the timing of when we expect to recognize revenue. Generally, our contract liabilities are expected to be recognized in one year or less. Customer deposits and deferred revenue are separately stated in our Consolidated Balance Sheet. Summary of changes in contract assets and liabilities for the period from January 1, 2018 to December 31, 2018: Contract assets Contract assets, January 1, 2018 $ 67,000 Contract assets at beginning of year transferred to accounts receivable (43,000 ) Reversal of contract assets due to changes in transaction price (24,000 ) Contract assets recorded on contracts during the period 36,000 Contract assets, December 31, 2018 $ 36,000 Contract liabilities Contract liabilities, January 1, 2018 $ 146,000 Recognition of revenue included in beginning of year contract liabilities (138,000 ) Contract liabilities, net of revenue recognized on contracts during the period 263,000 Contract liabilities, December 31, 2018 $ 271,000 The following table presents our disaggregated revenue by geographic region and source: Year Ended December 31, 2017 2018 Revenue by geographic region: United States $ 574,000 $ 447,000 Switzerland 79,000 77,000 Total revenue $ 653,000 $ 524,000 Revenue by source: Design services $ 613,000 $ 365,000 Royalties 40,000 159,000 Total revenue $ 653,000 $ 524,000

INVESTMENTS HELD-TO-MATURITY

INVESTMENTS HELD-TO-MATURITY	12 Months Ended
	Dec. 31, 2018
Investments [Abstract]
INVESTMENTS HELD-TO-MATURITY	INVESTMENTS HELD-TO-MATURITY We classify investments as held-to-maturity when we have the positive intent and ability to hold the securities to maturity. During 2017, we invested in commercial papers and certificates of deposit that were classified as investments held-to-maturity. As of December 31, 2017, all of our investments held-to-maturity had matured and we had no investments classified as held-to-maturity. During 2018, we invested in U.S. Treasury bills, commercial papers and a certificate of deposit that were classified as investments held-to-maturity. As of December 31, 2018, both amortized cost value and fair value were $16.9 million with zero unrealized gain or loss. U.S. Treasury bills totaling $25.0 million matured in April 2018 and certain commercial papers totaling $14.6 million matured during the year ended December 31, 2018. Remaining commercial papers totaling $16.9 million mature in January 2019, and the certificate of deposit for $100,000 matures in January 2019. We did not recognize an other-than-temporary impairment or a comprehensive gain or loss for the year ended December 31, 2018. We recorded interest and investment income of $67,000 and $481,000 for the years ended December 31, 2017 and 2018, respectively, associated with our cash and investment accounts.

PROPERTY AND EQUIPMENT, NET

PROPERTY AND EQUIPMENT, NET	12 Months Ended
	Dec. 31, 2018
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT, NET	PROPERTY AND EQUIPMENT, NET Property and equipment, net, consists of the following: As of December 31, 2017 As of December 31, 2018 Cost: Computers, peripheral and scientific equipment $ 1,016,000 $ 1,350,000 Software 1,367,000 1,749,000 Leasehold improvements 502,000 294,000 Office furniture and equipment 327,000 391,000 3,212,000 3,784,000 Less: Accumulated depreciation and amortization (1,858,000 ) (1,797,000 ) Property and equipment, net $ 1,354,000 $ 1,987,000 Depreciation for the years ended December 31, 2017 and December 31, 2018 was $595,000 and $704,000 , respectively. Cost basis of assets disposed for the years ended December 31, 2017 and December 31, 2018 was $21,000 and $773,000 , respectively. The disposals in 2018 were primarily a result of relocating our corporate offices and writing off the fully amortized leasehold improvements related to our former office.

INTANGIBLE ASSETS, NET, AND GOO

INTANGIBLE ASSETS, NET, AND GOODWILL	12 Months Ended
	Dec. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS, NET, AND GOODWILL	INTANGIBLE ASSETS, NET, AND GOODWILL Intangible assets include patents, domain name and other intangibles purchased from GVR, including customer relationships, technology and a trademark. Certain patents were acquired from STI as a result of an asset contribution and were recorded at their carryover basis. The fair value of the patents remained substantially the same as their carrying value at the exchange date. In addition, we acquired other patents and the domain name www.resonant.com through the normal course of business. Intangibles acquired as part of the purchase of GVR were initially recorded at their fair value. Issued patents are amortized over their approximate useful life of 17 years, or 20 years in the case of new patents, once they are approved by their respective regulatory agency. For the patents acquired from STI, we are amortizing them over the remaining useful life of 1 to 11 years as of December 31, 2018 . The domain name is amortized over the approximate useful life of 10 years. The other intangibles acquired from GVR are amortized over their useful life of three to five years. Intangible assets, net, consists of the following: As of December 31, 2017 As of December 31, 2018 Cost: Patents $ 1,349,000 $ 1,507,000 Domain name 22,000 22,000 Client Base (1) 143,000 142,000 Trademark (1) 17,000 17,000 Backlog (1) 13,000 13,000 Technology 77,000 77,000 1,621,000 1,778,000 Less: Accumulated amortization (268,000 ) (404,000 ) Intangible assets, net $ 1,353,000 $ 1,374,000 (1) Includes the impact of foreign currency translation. The total impact at December 31, 2017 was $2,000 and the total impact at December 31, 2018 was $1,000 . During the year ended December 31, 2017 and 2018, we wrote-off $8,000 and $96,000 , respectively, of patents we are no longer pursuing. The write-offs are included in research and development expense. There were no impairments to any other intangibles. Amortization of intangible assets was $126,000 and $136,000 for the years ended December 31, 2017 and 2018 , respectively. The following table summarizes the estimated amortization expense relating to the intangible assets as of December 31, 2018 : Years ending December 31, 2019 $ 112,000 2020 85,000 2021 76,000 2022 65,000 2023 63,000 2024 and thereafter 466,000 Total amortization expense $ 867,000 Goodwill represents the excess of the purchase price over the fair value of the net assets acquired from GVR Trade. Goodwill is not amortized, but is subject to impairment tests on at least an annual basis and whenever circumstances suggest that goodwill may be impaired. The following table summarizes goodwill arising from the acquisition of GVR Trade: Goodwill Balance at January 1, 2017 $ 789,000 Effect of currency translation 35,000 Balance at December 31, 2017 $ 824,000 Effect of currency translation (7,000 ) Balance at December 31, 2018 $ 817,000

WARRANTS

WARRANTS	12 Months Ended
	Dec. 31, 2018
Warrants and Rights Note Disclosure [Abstract]
WARRANTS	WARRANTS From time to time, we have issued warrants to purchase shares of common stock. These warrants have been issued in connection with financing transactions and for consulting services. Our warrants are subject to standard anti-dilution provisions applicable to shares of our common stock. Bridge Warrants In connection with and as an inducement to make the bridge loans in January and March 2013 , Resonant LLC issued to each of our three founders 5 -year warrants to purchase Class B units of Resonant LLC at an exercise price of $0.40 per unit, which we refer to as the Bridge Warrants. The Bridge Warrants were issued in two tranches, at the same time the bridge loan was funded, with each founder receiving warrants for 20,833 Class B units on each of January 31, 2013 (for a total of 62,499 Class B units) and March 19, 2013 (for a total of 62,499 Class B units). The founders paid an aggregate of $1,000 in cash for the Bridge Warrants. On June 17, 2013 , in connection with our acquisition of all of the outstanding membership interests of Resonant LLC in an exchange transaction, the founders exchanged their Bridge Warrants to purchase an aggregate of 124,998 Class B units of Resonant LLC for Bridge Warrants to purchase an aggregate of 249,999 shares of our common stock at an exercise price of $0.20 per share. All other terms of the Bridge Warrants remained the same. In January 2018, we entered into an agreement with our founders to exchange all of the warrants for an amount of shares that would equal the number of shares they would have received if exercised under a cashless exercise. The effect of exchanging the warrants for shares of our common stock was considered a modification of the award which required us to record expense for the excess of the fair value of the common stock issued over the fair value of the exchanged warrants. On the date of the exchange the fair value of the warrants was determined to be $1.6 million and the fair value of the shares of common stock issued were $1.6 million . There was a difference in fair value of $2,000 which was recorded to sales, marketing and administration expenses during the year ended December 31, 2018. Consulting Warrant, Financing Warrant and Underwriting Warrant Upon consummation of our Senior Convertible Note financing in June 2013, we issued warrants for business consulting services provided by MDB Capital Group, LLC, or MDB. We issued a 7 -year warrant to purchase 222,222 shares of our common stock at an exercise price of $0.01 per share, which we refer to as the Consulting Warrant. The Consulting Warrant is exercisable six months after the completion of our initial public offering, or IPO, in 2014 and expires June 17, 2020 . In addition, for placement agent services provided by MDB in connection with our Senior Convertible Note financing, we issued to MDB a 7 -year warrant to purchase 208,763 shares of our common stock at an exercise price of $3.35 per share, which we refer to as the Financing Warrant. The Financing Warrant is exercisable six months after the completion of our IPO and expires June 17, 2020 . In connection with the closing of our IPO, we also issued a third warrant to MDB related to their role as the sole underwriter for our IPO, which we refer to as the Underwriting Warrant. We issued them a 5 -year warrant to purchase 310,500 shares of common stock at an exercise price of $7.50 per share. The warrant was not exercisable until November 24, 2014 ( 180 -days from the date of the underwriting agreement) and expires May 28, 2019 . Investor Relations Warrant In August 2014 and October 2014 , we entered into agreements with our investor relations firm, or IR Firm, and an IR consultant to provide us with investor relations services. Pursuant to the IR Firm agreement, in addition to monthly cash compensation, we issued to the IR Firm a 3 -year consulting warrant, or IR Consulting Warrant, for the purchase of 42,000 shares of common stock that became fully vested on July 21, 2015 . The IR Consulting Warrant had an exercise price of $8.31 and expired, unexercised, on July 17, 2017 . Pursuant to our agreement with the IR consultant, in addition to monthly cash compensation, we issued to the IR consultant a 4 -year consulting warrant, or IR Warrant, for the purchase of 6,000 shares of common stock that became fully vested on September of 2015. The IR Warrant had an exercise price of $6.50 and expired on September 30, 2018 . There was no expense recorded for the years ended December 31, 2017 or 2018 related to the investor relations warrants as they had been fully expensed as of December 31, 2015 . Private Placement Warrants - 2016 In April 2016 , we issued warrants to purchase 1,996,880 shares of our common stock at an exercise price of $2.86 in connection with our private placement sale of 1,996,880 shares of common stock. The warrants are exercisable for a period commencing October 2016 and expire on April 25, 2019 . We also issued to the placement agents in the financing, warrants to purchase an aggregate of 99,844 shares of our common stock at an exercise price of $2.86 for a period commencing 6 months and ending 36 months after the closing. We refer to these warrants as Private Placement Warrants - 2016 . We estimated the fair value of the Private Placement Warrants - 2016 at $2,500,000 using the Black-Scholes option valuation model with the following assumptions: market prices of the stock of $2.90 per share, time to maturity of 3 years , volatility of 60% , zero expected dividend rate and risk free rate of 0.97% . The allocation of the fair value of these warrants was included in additional paid-in capital on the consolidated balance sheet. In December 2017 , we entered into Warrant Exercise Agreements with certain holders of Private Placement Warrants - 2016 to induce the exercise of 836,780 warrants in full. Pursuant to the agreements, the warrant holders exercised in full the warrants and purchased an aggregate of 836,780 shares of our common stock at an exercise price of $2.86 per share, for an aggregate exercise price of approximately $2.4 million and we paid the warrant holders aggregated inducement fees of approximately $239,000 , which resulted in net proceeds to us of $2.2 million . The inducement offer included in the Warrant Exercise Agreements was considered a modification to the warrants upon acceptance by the warrant holders. Upon modification of the warrants we were required to remeasure the fair value of the warrants. We estimated the fair value of the Private Placement Warrants - 2016 immediately prior to modification at $3.8 million using the Black-Scholes option valuation model with the following assumptions: market prices of the stock of $6.96 to $7.42 per share, time to maturity of 1.42 years, volatility of 60% , zero expected dividend rate and risk free rates of 1.70% to 1.74% . We estimated the fair value of the Private Placement Warrants - 2016 upon modification at $3.9 million using the Black-Scholes option valuation model with the following assumptions: market prices of the stock of $6.96 to $7.42 per share, time to maturity of 1 day , volatility of 10% , zero expected dividend rate and risk free rates of 1.14% to 1.21% . The change in fair value was $166,000 , and when combined with the cash inducement of $239,000 , resulted in $73,000 of expense, which was recorded as warrant inducement expense. Underwriting Warrants - Public Offering 2016 In September 2016 , we issued warrants to purchase 135,750 shares of our common stock at an exercise price of $4.25 to the underwriter of our public offering of 2,715,000 shares of common stock. The warrants are exercisable for a 2 year period commencing September 9, 2017 . We refer to these warrants as Underwriting Warrants - Public Offering 2016. We estimated the fair value of the Underwriting Warrants -Public Offering 2016 at $475,000 using the Black-Scholes option valuation model with the following assumptions: market prices of the stock of $6.54 per share, time to maturity of 3 years , volatility of 60% , zero expected dividend rate and risk free rate of 0.90% . The allocation of the fair value of these warrants was included in additional paid-in capital on the consolidated balance sheet. Private Placement Warrants - February 2017 In February 2017 , we issued warrants to purchase 1,626,898 shares of our common stock at an exercise price of $8.25 in connection with our private placement sale of 1,626,898 shares of common stock. The warrants were exercisable for a period commencing 6 months and ending 30 months after the closing of the financing. We refer to these warrants as Private Placement Warrants - February 2017 . We estimated the fair value of the Private Placement Warrants - February 2017 at $2,084,000 using the Black-Scholes option valuation model with the following assumptions: market prices of the stock of $4.91 per share, time to maturity of 3 years , volatility of 60% , zero expected dividend rate and risk free rate of 1.50% . The allocation of the fair value of these warrants was included in additional paid-in capital on the consolidated balance sheet. On December 19, 2017, we entered into a Warrant Exercise Agreement with the holder of Private Placement Warrants - February 2017 to induce the exercise of the 1,626,898 warrants in full. Pursuant to the agreement, the warrant holder exercised in full the warrant and purchased 1,626,898 shares of our common stock at an exercise price of $8.25 per share, for an aggregate exercise price of approximately $13.4 million and we paid the warrant holder an inducement fee of approximately $6.7 million , which resulted in net proceeds to us of $6.7 million . The inducement offer included in the Warrant Exercise Agreement was considered a modification to the warrant upon acceptance by the warrant holder. Upon modification of the warrant we were required to remeasure the warrant. We estimated the fair value of the Private Placement Warrants - February 2017 immediately prior to modification at $4.1 million using the Black-Scholes option valuation model with the following assumptions: market prices of the stock of $8.18 per share, time to maturity of 1.67 years , volatility of 60% , zero expected dividend rate and risk free rate of 1.78% . We estimated the fair value of the Private Placement Warrants - February 2017 upon modification at $6.7 million using the Black-Scholes option valuation model with the following assumptions: market prices of the stock of $8.18 per share, time to maturity of 1 day , volatility of 10% , zero expected dividend rate and risk free rate of 1.25% . The change in fair value was $4.1 million , and when combined with the cash inducement of $6.7 million , resulted in $2.6 million of expense, which was recorded as warrant inducement expense. Private Placement Warrants - September 2017 In September and October 2017, we issued warrants to purchase an aggregate of 1,976,919 shares of our common stock at an exercise price of $4.85 in connection with our private placement sale of 1,976,919 shares of common stock. The sale was completed in two tranches with the first tranche, which closed on September 28, 2017 , including 1,745,581 warrants, and the second tranche, which closed on October 2, 2017 , including 231,338 warrants. The warrants are exercisable for a period commencing 6 months after the closing of the financing and expire on September 28, 2020. Collectively, we refer to these warrants as Private Placement Warrants - September 2017. We estimated the total fair value of the Private Placement Warrants - September 2017 at $3.6 million using the Black-Scholes option valuation model with the following assumptions: market prices of the stock of $4.49 for the first tranche and $4.69 per share for the second tranche, time to maturity of 3 years , volatility of 60% , zero expected dividend rate and risk free rates of 1.59% for the first tranche and 1.63% for the second tranche. The allocation of the fair value of these warrants was included in additional paid-in capital on the consolidated balance sheet. Placement Agent Warrants - 2017 In addition to the Private Placement Warrants - September 2017 issued in connection with our private placement sale of 1,976,919 shares of our common stock, we also issued to the placement agent, warrants to purchase a total of 98,846 shares of our common stock at an exercise price of $4.85 per share. Upon closing of the first tranche on September 28, 2017, we issued 87,279 warrants, and upon closing the second tranche, we issued 11,567 warrants. The warrants are exercisable for a period commencing 6 months after the closing of the financing and expire on September 28, 2020 . Collectively, we refer to these warrants as Placement Agent Warrants - 2017. We estimated the fair value of the Placement Agent Warrants - 2017 at $174,000 using the Black-Scholes option valuation model with the following assumptions: market prices of the stock of $4.49 per share for the first tranche and $4.69 per share for the second tranche, time to maturity of 3 years , volatility of 60% , zero expected dividend rate and risk free rates of 1.59% for the first tranche and 1.63% for the second tranche. The allocation of the fair value of these warrants was included in additional paid-in capital on the consolidated balance sheet. A roll-forward of warrant activity from January 1, 2017 to December 31, 2017 is shown in the following table: Issued and Warrants Warrants Issued and Bridge Warrants 249,999 — — 249,999 Consulting Warrant 98,000 — (85,777 ) (1) 12,223 Financing Warrant 78,186 — (15,656 ) (2) 62,530 Underwriting Warrant 310,500 — — 310,500 IR Consulting Warrant 48,000 — (42,000 ) (3) 6,000 Private Placement Warrants - 2016 1,995,124 — (1,104,061 ) (4) 891,063 Underwriting Warrants - Public Offering 2016 135,750 — (13,575 ) (5) 122,175 Private Placement Warrants - February 2017 — 1,626,898 (1,626,898 ) (6) — Private Placement Warrants - September 2017 — 1,976,919 — 1,976,919 Placement Agent Warrants - 2017 — 98,846 — 98,846 2,915,559 3,702,663 (2,887,967 ) 3,730,255 (1) During the year ended December 31, 2017, there were 85,777 warrants that were exercised through cashless exercises, which netted 85,620 shares being issued. (2) During the year ended December 31, 2017, there were 15,656 warrants that were exercised through cashless exercises, which netted 6,842 shares being issued. (3) During the year ended December 31, 2017, 42,000 warrants expired. (4) During the year ended December 31, 2017, there were 122,281 warrants that were exercised through cashless exercises, which netted 49,063 shares being issued. Additionally, there were 981,780 warrants that were exercised for cash, which included 836,780 warrants exercised subject to inducement, which offered the warrant holder an inducement fee of $0.29 /share to exercise the warrant in full for cash immediately. (5) During the year ended December 31, 2017, there were 13,575 warrants that were exercised through cashless exercises, which netted 6,322 shares being issued. (6) During the year ended December 31, 2017, there were 1,626,898 warrants that were exercised for cash. The warrants were exercised subject to inducement, which offered the warrant holder an inducement fee of $4.13 /share to exercise the warrant in full for cash immediately. A roll-forward of warrant activity from January 1, 2018 to December 31, 2018 is shown in the following table: Exercise Price Expiration Date Issued and Warrants Issued and Bridge Warrants NA NA 249,999 (249,999 ) (1) — Consulting Warrant $0.01 6/17/2020 12,223 (5,556 ) (2) 6,667 Financing Warrant $3.35 6/17/2020 62,530 — 62,530 Underwriting Warrant $7.50 5/28/2019 310,500 — 310,500 IR Consulting Warrant NA NA 6,000 (6,000 ) (3) — Private Placement Warrants - 2016 $2.86 4/25/2019 891,063 (73,000 ) (4) 818,063 Underwriting Warrants - Public Offering 2016 $4.25 9/9/2019 122,175 — 122,175 Private Placement Warrants - September 2017 $4.85 9/28/2020 1,976,919 (10,600 ) (5) 1,966,319 Placement Agent Warrants - 2017 $4.85 9/28/2020 98,846 — 98,846 3,730,255 (345,155 ) 3,385,100 (1) During the year ended December 31, 2018, there were 249,999 warrants that were exchanged for 242,913 shares of common stock in an exchange transaction where the warrant holders exchanged the warrants for the same number of shares they would have been entitled to in a cashless exercise. (2) During the year ended December 31, 2018, there were 5,556 warrants that were exercised through a cashless exercise, which netted 5,542 shares being issued. (3) During the year ended December 31, 2018, 6,000 warrants expired. (4) During the year ended December 31, 2018, there were 73,000 warrants exercised for cash. (5) During the year ended December 31, 2018, there were 10,600 warrants exercised for cash.

STOCKHOLDERS' EQUITY

STOCKHOLDERS' EQUITY	12 Months Ended
	Dec. 31, 2018
Stockholders' Equity Note [Abstract]
STOCKHOLDERS' EQUITY	STOCKHOLDERS’ EQUITY AND EARNINGS PER SHARE Common Stock Pursuant to our amended and restated certificate of incorporation, we are authorized to issue 47,000,000 shares of common stock. Holders of our common stock are entitled to dividends as and when declared by the board of directors, subject to rights and holders of all classes of stock outstanding having priority rights to dividends. There have been no dividends declared to date. Each share of common stock is entitled to one vote. On February 22, 2017 , we completed the private placement sale of 1,626,898 units at a price of $4.61 per unit to one investor. Each unit consists of one share of our common stock and one warrant to purchase one share of our common stock at an exercise price of $8.25 for a period commencing 6 months and ending 30 months after the closing of the financing. Gross proceeds were $7.5 million . We incurred $29,000 of legal expenses in connection with the financing. We registered for resale by the investor the shares of common stock, and the shares of common stock issuable upon exercise of the warrants, purchased by the investor in the financing pursuant to a registration statement that was declared effective by the SEC in April 2017 . On October 2, 2017 , we completed the private placement sale of 1,976,919 units. Each unit consisted of one share of our common stock and one warrant to purchase one share of our common stock at an exercise price of $4.85 per share for a period commencing 6 months and ending 36 months from September 28, 2017 , the date of the first closing of the offering. The sale closed in two rounds with the first closing on September 28, 2017 which included the private placement sale of 1,745,581 units at a price of $4.70 per unit to institutional and individual investors. Gross proceeds in the first closing were $8.2 million with net proceeds of $7.5 million after deducting placement agent fees and offering expenses. The second closing, completed on October 2, 2017 , was for 231,338 units and gross proceeds of $1.1 million with net proceeds of $1.0 million after deducting placement agent fees and offering expenses. We also issued to the placement agent, warrants to purchase an aggregate of 98,846 shares of our common stock at an exercise price of $4.85 per share for a period commencing 6 months and ending 36 months from September 28, 2017 . On March 27, 2018, we completed the sale of 5,714,286 shares of common stock at a price of $3.50 per share in an underwritten public offering. Gross proceeds were $20.0 million with net proceeds of $18.4 million after deducting underwriter fees and offering expenses. The shares were issued pursuant to a shelf registration statement that we filed with the SEC, which became effective in May 2016. On April 6, 2018, following exercise by the underwriter of its overallotment option, we sold an additional 857,142 shares at a price of $3.50 , resulting in gross proceeds of $3.0 million and net proceeds of $2.8 million after deducting underwriter fees and offering expenses. We have a Form S-3 universal shelf registration statement on file with the SEC. The universal shelf registration statement on Form S-3 permits us to sell, in one or more public offerings, shares of our common stock, shares of preferred stock or debt securities, or any combination of such securities and warrants to purchase securities, for proceeds in an aggregate amount of up to $50.0 million, subject to potential limitations on the amount of securities we may sell in any twelve-month period. The Form S-3 will expire in November 2021 . No securities have been issued pursuant to the registration statement. Preferred Stock Pursuant to our amended and restated certificate of incorporation, we are authorized to issue 3,000,000 shares of preferred stock. The board of directors has the authority, without action by our stockholders, to designate and issue shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof. To-date, no preferred shares have been issued. Stock Repurchase Program On November 26, 2018, we announced that our board of directors had authorized a program to repurchase up to $4.0 million of our common stock over a 12-month period, either in the open market or through privately negotiated transactions. During the year ended December 31, 2018, we repurchased and retired 80,100 shares of common stock, at an aggregate cost of approximately $152,000 , including commissions, or an average price of $1.88 per share. Earnings Per Share The following table presents the number of shares excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods below: Year Ended December 31, 2017 Year Ended December 31, 2018 Common stock warrants 3,730,255 3,385,100 Common stock options 1,082,490 1,255,280 Non-vested restricted stock unit awards 1,476,858 1,921,594 Total shares excluded from net loss per share attributable to common stockholders 6,289,603 6,561,974

STOCK-BASED COMPENSATION

STOCK-BASED COMPENSATION	12 Months Ended
	Dec. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
STOCK-BASED COMPENSATION	STOCK-BASED COMPENSATION 2014 Omnibus Incentive Plan In January 2014, our board of directors approved the 2014 Omnibus Incentive Plan and amended and restated the plan in March 2014. Our stockholders approved the Amended and Restated 2014 Omnibus Incentive Plan, or the 2014 Plan, in March 2014. Our 2014 Plan initially permitted the issuance of equity-based instruments covering up to a total of 1,400,000 shares of common stock. In June 2016, our board of directors and stockholders approved an increase of 1,300,000 shares and in June 2017 approved an additional increase of 3,250,000 shares of common stock bringing the total shares allowed under the plan to 5,950,000 . As of December 31, 2018, there were 1,189,389 shares available to issue under the 2014 Plan. Option Valuation We have computed the fair value of options granted to employees and non-employees using the Black-Scholes option valuation model. The compensation costs of non-employee arrangements are subject to re-measurement at each reporting period over the vesting terms as earned. Option forfeitures are estimated at the time of valuation and reduce expense ratably over the vesting period. This estimate will be adjusted periodically based on the extent to which actual option forfeitures differ, or are expected to differ, from the previous estimate, when it is material. The expected term used for options issued to non-employees is the contractual life and the expected term used for options issued to employees is the estimated period of time that options granted are expected to be outstanding. We have estimated the expected life of our employee stock options using the “simplified” method, whereby, the expected life equals the arithmetic average of the vesting term and the original contractual term of the option due to our lack of sufficient historical data. For non-employees we use an estimated expected life of the remaining term of the stock option grant, which is initially ten years . Since our stock has not been publicly traded for a sufficiently long period of time, we are utilizing an expected volatility figure based on a review of the historical volatilities, over a period of time, equivalent to the expected life of the instrument being valued, of similarly positioned public companies within our industry. The risk-free interest rate was determined from the U.S. Treasury's Daily Treasury Yield Curve Rate with a term that best approximates the expected term of the instrument being valued. Stock Options to Employees and Non-Employees During the years ended December 31, 2017 and 2018 , we granted incentive stock options for the purchase of 488,300 and 252,500 shares, respectively, of our common stock to our employees and non-employees. The options granted in 2017 have an exercise price range of $4.36 to $7.80 per share with a term of ten years. The options granted in 2018 have an exercise price range of $1.80 to $5.96 per share with a term of ten years. The options vest over various periods, generally quarterly over sixteen quarters. The options granted in 2017 had an aggregate grant date fair value of $1.4 million and the options granted in 2018 had an aggregate grant date fair value of $779,000 utilizing the Black-Scholes option valuation model. We estimated the fair value of stock options awarded during the years ended December 31, 2017 and 2018 using the Black-Scholes option valuation model. The fair values of stock options granted for the years were estimated using the following assumptions: Option Grants Awarded During the Year Ended December 31, 2017 Option Grants Awarded During the Year Ended December 31, 2018 Stock Price $4.36 - $7.80 $1.80 - $5.96 Dividend Yield 0% 0% Expected Volatility 60.0% 70.0% Risk-free interest rate 1.95% - 2.37% 2.50% - 3.09% Expected Term 7 to 10 years 7 years Stock-based compensation expense related to stock options for employees was $435,000 and $469,000 for the years ended December 31, 2017 and 2018, respectively. We estimate forfeitures at the time of grant and revise those estimates in subsequent periods if actual forfeitures differ from our estimates. We use historical data to estimate pre-vesting option forfeitures and record stock-based compensation expense only for those awards that are expected to vest. To the extent that actual forfeitures differ from our estimates, the difference is recorded as a cumulative adjustment in the period the estimates were revised. For the years ended December 31, 2017 and 2018, we applied a forfeiture rate of six percent, which is reflected in our stock-based compensation expense related to stock options. In January 2017, we modified certain stock options previously granted to a former executive. The modification was made in connection with the executive’s termination. The modification included accelerated vesting of stock options to purchase 8,752 shares of common stock as well as an extension of the exercise period for all vested shares, including stock options to purchase 17,504 shares of common stock. As a result of the modification, additional stock compensation expense of $19,000 was recognized for the year ended December 31, 2017. There was no expense related to the modification for the year ended December 31, 2018. For stock options paid in consideration of services rendered by non-employees, we recognize compensation expense in accordance with the requirements of ASC 505-50. Non-employee stock option grants that do not vest immediately upon grant are recorded as an expense over the vesting period. At the end of each financial reporting period prior to performance, the value of these stock options, as calculated using the Black-Scholes option valuation model, is determined, and compensation expense recognized or recovered during the period is adjusted accordingly. Since the fair market value of stock options granted to non-employees is subject to change in the future, the amount of the future compensation expense is subject to adjustment until the common stock options are fully vested. Stock-based compensation expense related to stock options for non-employees was $9,000 and $7,000 for the years ended December 31, 2017 and 2018 , respectively. Stock Option Award Activity The following is a summary of our stock option activity during the year ended December 31, 2017 : Number of Options Weighted Average Exercise Price Weighted Average Grant Date Fair Value Weighted Average Remaining Life In Years Outstanding, January 1, 2017 801,690 $ 5.25 $ 3.32 7.40 Granted 488,300 4.62 2.79 9.51 Exercised (32,928 ) 2.37 1.41 — Canceled/Forfeited (174,572 ) 6.40 4.18 — Outstanding, December 31, 2017 1,082,490 $ 4.87 $ 3.00 8.38 Number of Options Weighted Average Exercise Price Weighted Average Grant Date Fair Value Weighted Average Remaining Life In Years Exercisable, January 1, 2017 419,174 $ 5.94 $ 3.86 6.00 Vested 457,338 4.57 2.77 8.65 Exercised (32,928 ) 2.37 1.41 — Canceled/Forfeited (139,281 ) 6.65 4.38 — Exercisable, December 31, 2017 704,303 $ 5.08 $ 3.17 8.15 The following is a summary of our stock option activity during the year ended December 31, 2018 : Number of Options Weighted Average Exercise Price Weighted Average Grant Date Fair Value Weighted Average Remaining Life In Years Outstanding, January 1, 2018 1,082,490 $ 4.87 $ 3.00 8.38 Granted 252,500 4.54 3.09 9.16 Exercised (4,692 ) 2.10 1.75 — Canceled/Forfeited (75,018 ) 4.72 2.89 — Outstanding, December 31, 2018 1,255,280 $ 4.82 $ 3.03 7.75 Number of Options Weighted Average Exercise Price Weighted Average Grant Date Fair Value Weighted Average Remaining Life In Years Exercisable, January 1, 2018 704,303 $ 5.08 $ 3.17 8.15 Vested 161,404 4.69 2.89 7.56 Exercised (4,692 ) 2.10 1.75 — Canceled/Forfeited (17,996 ) 4.72 2.84 — Exercisable, December 31, 2018 843,019 $ 5.02 $ 3.13 7.23 The following table presents information related to stock options outstanding and exercisable at December 31, 2018 : Options Outstanding Options Exercisable Exercise Price Outstanding Number of Options Weighted Average Remaining Life In Years Exercisable Number of Options $1.80 - $2.00 161,183 7.09 99,637 $3.25 - $4.92 652,297 8.41 393,944 $5.01 - $6.00 281,500 5.87 214,115 $6.18 – $7.20 70,000 5.97 55,004 $7.54 – $7.80 67,800 6.09 58,749 $8.06 - $12.98 22,500 6.05 21,570 1,255,280 7.23 843,019 As of December 31, 2018 , there was $1.1 million of unrecognized compensation expense related to unvested stock options, which is expected to be recognized over a weighted average vesting period of approximately 2.8 years. The aggregate intrinsic value of outstanding options and options vested as of December 31, 2017 were $2.9 million and $1.7 million , respectively, representing options whose exercise price was less than the closing fair market value of our common stock of $7.47 per share. The aggregate intrinsic value of outstanding options and options vested as of December 31, 2018 were zero as there were no options whose exercise price was less than the closing fair market value of our common stock of $1.33 per share. There were no excess tax benefits realized for tax deductions from stock options exercised during the years ended December 31, 2017 and 2018 as we have recorded a full valuation allowance against our deferred income taxes. Restricted Stock Units Activity We account for restricted stock units (RSUs) issued to employees at fair value, based on the market price of our stock on the date of grant, net of estimated forfeitures. The fair value of non-employee restricted stock units awarded are re-measured as the awards vest, and the resulting increase in fair value, if any, is recognized as expense in the period the related services are rendered. RSUs issued in connection with our employee incentive programs typically vest within 10 days of grant. All other RSUs, primarily issued as long term incentives, generally vest annually over three to four years. During the years ended December 31, 2017 and 2018 we recorded $3.6 million and $4.8 million , respectively, of stock-based compensation related to the restricted stock units that have been issued to-date. A summary of restricted stock unit activity for the year ended December 31, 2017 is as follows: Number of Restricted Share Units Weighted-Average Grant-Date Fair Value Per Share Outstanding at January 1, 2017 1,455,558 $ 3.64 Granted 722,400 5.37 Vested (649,359 ) 4.26 Forfeited (51,741 ) 5.40 Outstanding at December 31, 2017 1,476,858 $ 4.96 A summary of restricted stock unit activity for the year ended December 31, 2018 is as follows: Number of Restricted Share Units Weighted-Average Grant-Date Fair Value Per Share Outstanding at January 1, 2018 1,476,858 $ 4.96 Granted 1,661,750 4.60 Vested (1,051,939 ) 4.68 Forfeited (165,075 ) 5.17 Outstanding at December 31, 2018 1,921,594 $ 4.78 As of December 31, 2018 , there was $6.3 million of unrecognized compensation expense related to unvested restricted stock unit agreements which is expected to be recognized over a weighted-average period of approximately 2.1 years . For restricted stock unit awards subject to graded vesting, we recognize compensation cost on a straight-line basis over the service period for the entire award. Market-based Awards In August 2016, we granted 250,000 market-based restricted stock units to an executive. The restricted stock units are subject to market-based vesting requirements, measured quarterly, based on the average of (a) the average high daily trading price of our common stock for each trading day during the last month of the applicable calendar quarter and (b) the average low daily trading price of our common stock for each trading day during the last month of the applicable calendar quarter, each as reported by The Nasdaq Stock Market, LLC. The restricted stock units are eligible to be earned on a quarterly basis based on a linear interpolation of the applicable share price, or in the case of a liquidation event, on the day of (or in connection with) such liquidation event based on the applicable transaction price. Once earned, the restricted stock units vest 50% on the date such restricted stock units become earned and 50% on September 30, 2019 . We recognize compensation expense for restricted stock units with market-based conditions using a graded vesting model, based on the probability of the performance condition being met, net of estimated pre-vesting forfeitures. The share price on the date of issuance was $5.06 per share. To determine the fair value of the award, we used a Monte Carlo simulation, which simulates future stock prices for the Company and, hence, shares vested, pursuant to the award. A key input into the model is the expected volatility for our stock. This estimate considered the historical volatility of our stock as well as the stock price volatility of guideline public companies. The fair value was determined to be $74,000 . For each of the years ended December 31, 2017 and 2018, we recognized $24,000 of stock compensation expense in connection with this award, which is included in sales, marketing and administration expenses. The unamortized expense related to this award is $18,000 and is expected to be recognized over 0.8 years. Incentive Bonus Awards We provide eligible employees, including executives, the opportunity to earn bonus awards upon achievement of predetermined performance goals and objectives. The purpose is to reward attainment of company goals and/or individual performance objectives, with award opportunities expressed as a percentage of base salary. Bonuses can be measured and paid quarterly and/or annually, and are paid in cash, equity or a combination of cash and equity, at the discretion of our compensation committee. Total stock-based compensation recorded in the consolidated statements of comprehensive loss is allocated as follows: Year Ended Year Ended December 31, 2018 Research and development Employees $ 1,937,000 $ 2,479,000 Non-employees 181,000 77,000 Total research and development 2,118,000 2,556,000 Sales, marketing and administration Employees and directors 1,824,000 2,604,000 Non-employees 179,000 102,000 Total sales, marketing and administration 2,003,000 2,706,000 Total stock-based compensation $ 4,121,000 $ 5,262,000

COMMITMENT AND CONTINGENCIES

COMMITMENT AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
COMMITMENT AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES Purchase Commitments —We have non-cancelable purchasing commitments that we incur in the ordinary course of business. The purchase commitments covered by these agreements are for less than one year and aggregate to $193,000 as of December 31, 2018. Operating Leases —We lease facilities under non-cancelable operating leases. The leases expire between January 2022 and August 2024 and include renewal provisions for two to five years, provisions which require us to pay taxes, insurance, maintenance costs or provisions for minimum rent increases. Minimum lease payments, including scheduled rent increases, are recognized as rent expenses on a straight-line basis over the applicable lease term. One lease requires us to maintain a cash security deposit of $50,000 and also a $200,000 letter of credit in favor of the lessor. The letter of credit steps down $50,000 at each anniversary date if there have been no monetary defaults. The letter of credit is secured by a pledge in favor of the issuing bank of a $211,000 mutual fund account which is classified as restricted cash in our balance sheet. Rent expense related to our facilities was $477,000 and $663,000 , respectively, for the years ended December 31, 2017 and 2018 . Future minimum rent payments are as follows: Years ending December 31, 2019 $ 658,000 2020 726,000 2021 748,000 2022 557,000 2023 555,000 2024 and thereafter 376,000 Total future minimum rent payments $ 3,620,000 Legal Proceedings —We are not party to any legal proceedings. We may, from time to time, be party to litigation and subject to claims incident to the ordinary course of business. As our growth continues, we may become party to an increasing number of litigation matters and claims. The outcome of litigation and claims cannot be predicted with certainty, and the resolution of any future matters could materially affect our future financial position, results of operations or cash flows. Legal fees and other costs associated with such actions are expensed as incurred. We assess, in conjunction with our legal counsel, the need to record a liability for litigation and contingencies. Litigation accruals are recorded when and if it is determined that a loss related matter is both probable and reasonably estimable. Material loss contingencies that are reasonably possible of occurrence, if any, are subject to disclosure. We will evaluate developments in legal proceedings and other matters on a quarterly basis. As of December 31, 2017 and 2018 , there was no litigation or contingency with at least a reasonable possibility of a material loss. No losses have been recorded during the years ended December 31, 2017 and 2018 , respectively, with respect to litigation or loss contingencies. Intellectual Property Indemnities —We indemnify certain customers and manufacturers against liability arising from third-party claims of intellectual property rights infringement related to our products. These indemnities may appear in license agreements, development agreements and manufacturing agreements, may not be limited in amount or duration and generally survive the expiration date of the contract. Given that the amount of any potential liabilities related to such indemnities cannot be determined until an infringement claim has been made, we are unable to determine the maximum amount of losses that we could incur related to such indemnifications. Director and Officer Indemnities and Contractual Guarantees —We have entered into indemnification agreements with our directors and executive officers, which require us to indemnify such individuals to the fullest extent permitted by Delaware law. Our indemnification obligations under such agreements are not limited in amount or duration. Certain costs incurred in connection with such indemnifications may be recovered under certain circumstances under various insurance policies. Given that the amount of any potential liabilities related to such indemnities cannot be determined until a lawsuit has been filed, we are unable to determine the maximum amount of losses that we could incur relating to such indemnities. We have also entered into severance and change in control agreements with certain of our executives. These agreements provide for the payment of specific compensation benefits to such executives upon the termination of their employment with us. Guarantees and Indemnities —In the normal course of business, we are occasionally required to undertake indemnification for which we may be required to make future payments under specific circumstances. We review our exposure under such obligations no less than annually, or more frequently as required. The amount of any potential liabilities related to such obligations cannot be accurately determined until a formal claim is filed. Historically, any such amounts that become payable have not had a material negative effect our business, financial condition or results of operations. We maintain general and product liability insurance which may provide a source of recovery to us in the event of an indemnification claim.

INCOME TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2018
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES The provision for (benefit from) income taxes by jurisdiction consists of the following: Year Ended December 31, 2017 Year Ended December 31, 2018 U.S. federal: Current $ — $ — Deferred — — Total U.S. federal — — U.S. state and local: Current 1,000 2,000 Deferred — — Total U.S. state and local 1,000 2,000 Foreign: Current — — Deferred (15,000 ) (1,000 ) Total foreign (15,000 ) (1,000 ) Provision for (benefit from) income taxes $ (14,000 ) $ 1,000 Income taxes differ from the amounts computed by applying the U.S. federal income tax rate to pretax income (loss) before income taxes as a result of the following: Year Ended December 31, 2017 Year Ended December 31, 2018 Expected income tax benefit $ (7,357,000 ) $ (5,211,000 ) State income tax (benefit), net of federal benefit (1,176,000 ) (1,997,000 ) Valuation allowance 7,398,000 7,372,000 Permanent differences: Stock options 95,000 285,000 Warrants 914,000 — Research & development credit (263,000 ) (405,000 ) Adjustment to deferred taxes 267,000 (68,000 ) Foreign rate differential 19,000 2,000 Other 89,000 23,000 Provision for (benefit from) for income taxes $ (14,000 ) $ 1,000 For the years ended December 31, 2017 we recorded a net income tax benefit of $14,000 and for the year ended December 31, 2018 we recorded a tax provision of $1,000 . The net income tax benefit recorded in 2017 included $1,000 of income tax expense offset by $15,000 for the change in deferred foreign taxes. Deferred income tax reflects the tax effects of temporary differences that gave rise to significant portions of our deferred tax assets and liabilities. Deferred income tax consists of the following: As of December 31, 2017 As of December 31, 2018 U.S. federal and state deferred tax assets—long term: Accrued payroll $ 376,000 $ 102,000 Accrued expenses 21,000 45,000 Fixed assets 111,000 — Intangibles 457,000 418,000 Research & development credit 1,464,000 2,239,000 Net operating loss 13,204,000 20,140,000 Stock compensation 539,000 612,000 New jobs credit 8,000 8,000 Total long-term assets 16,180,000 23,564,000 Total deferred tax assets 16,180,000 23,564,000 U.S. federal and state deferred tax liabilities—long term: Fixed assets — (16,000 ) Total deferred tax liabilities — (16,000 ) Net deferred tax assets - long term 16,180,000 23,548,000 Less: Valuation allowance (16,180,000 ) (23,548,000 ) Net deferred tax assets $ — $ — Foreign deferred tax assets—long term: Net operating loss $ 12,000 $ 9,000 Total foreign deferred tax assets 12,000 9,000 Foreign deferred tax liabilities—long term: Intangibles (13,000 ) (4,000 ) Total foreign deferred tax liabilities (13,000 ) (4,000 ) Net foreign deferred tax assets (liabilities) (1,000 ) 5,000 Less: Valuation allowance — (5,000 ) Net deferred tax assets (liabilities) $ (1,000 ) $ — In December 2017, the Tax Cuts and Jobs Act (the “2017 Tax Act”) was enacted. The 2017 Tax Act represents major tax reform legislation that, among other provisions, reduced the U.S. corporate tax rate. The reduction in the tax rate reduced our federal and state net deferred tax assets by $6.1 million , primarily related to our net operating loss carryforwards. Due to the full valuation allowance recorded against our federal and state net deferred tax assets, there was no impact to our income tax expense for the year ended December 31, 2018 . We recorded a full valuation allowance against our U.S. federal and state net deferred tax assets at December 31, 2017 and December 31, 2018 . In determining the need for a valuation allowance, we reviewed all available evidence pursuant to the requirements of FASB ASC Topic 740, Income Taxes . Based upon our assessment of all available evidence, we have concluded that it is more likely than not that the net deferred tax assets will not be realized. For the year ended December 31, 2017 , the valuation allowance increased by $1.3 million . For the year ended December 31, 2018 , the valuation allowance increased by $7.4 million . As of December 31, 2018 , we had federal net operating loss carryforwards of approximately $71.6 million , state net operating loss carryforwards of approximately $72.9 million and foreign net operating loss carryforwards of $61,000 in Switzerland. In accordance with the 2017 Tax Act, the $24.9 million federal net operating loss carryforwards generated on or after January 1, 2018 will not expire and will be limited to 80% usage. The federal net operating loss carryforwards generated prior to January 1, 2018 will begin to expire in 2033, and the state net operating loss carryforwards will begin to expire in 2033. Our ability to utilize net operating loss carryforwards may be limited in the event that a change in ownership, as defined in Section 382 of the Internal Revenue Code, occurs in the future. In the event a change of ownership occurs, it will limit the annual usage of the carryforwards in future years. Management believes that certain changes in control have occurred which resulted in limitations on our net operating loss carryforwards; however, management has determined that these limitations will not impact the ultimate utilization of the net operating loss carryforwards. We recognize interest and penalties related to income tax matters in income taxes, and there were none during the years ended December 31, 2017 and 2018 . The adoption of ASC 740 guidance required us to identify, evaluate and measure all uncertain tax positions taken or to be taken on tax returns and to record liabilities for the amount of these positions that may not be sustained, or may only partially be sustained, upon examination by the relevant taxing authorities. Although we believe that our estimates and judgments were reasonable, actual results may differ from these estimates. Some or all of these judgments are subject to review by the taxing authorities. We have no significant uncertain tax positions for the years ended December 31, 2017 and 2018 . Our annual income taxes and the determination of the resulting deferred tax assets and liabilities involve a significant amount of judgment. Our judgments, assumptions and estimates relative to current income taxes take into account current tax laws, their interpretation of current tax laws and possible outcomes of future audits conducted by domestic tax authorities. We operate within federal and state taxing jurisdictions and are subject to audit in these jurisdictions. These audits can involve complex issues which may require an extended period of time to resolve. We are currently not being examined by any tax authorities. We are subject to taxation in the United States, California, Massachusetts and Switzerland. As of December 31, 2018 , our tax years remain open to examination by the taxing authorities for all years since our incorporation in 2013.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	12 Months Ended
	Dec. 31, 2018
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	RELATED PARTY TRANSACTIONS In August 2016, we entered into a consulting agreement with a member of our board of directors. Under the agreement, the board member would provide engineering design and fabrication advisory services for an hourly rate, with total payments not to exceed $120,000 during any twelve-month period. During the year ended December 31, 2017, we incurred expenses of $26,000 in connection with the consulting agreement. The agreement was terminated effective April 1, 2017. There was no expense for the year ended December 31, 2018.

EMPLOYEE BENEFIT PLAN

EMPLOYEE BENEFIT PLAN	12 Months Ended
	Dec. 31, 2018
Retirement Benefits [Abstract]
EMPLOYEE BENEFIT PLAN	EMPLOYEE BENEFIT PLAN We have a 401(k) Savings Retirement Plan that covers substantially all domestic employees who meet the plan’s eligibility requirements and provides for an employee elective contribution and employer matching contributions. We recorded matching contributions to the retirement plan of $284,000 and $372,000 for the years ended December 31, 2017 and 2018 , respectively.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2018
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	SUBSEQUENT EVENTS In February 2019 we received approximately $400,000 from the exercise of Private Placement Warrants - 2016, which resulted in the issuance of 140,000 shares of our common stock.

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Basis of Presentation and Use of Estimates	Basis of Presentation and Use of Estimates —The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or U.S. GAAP. In the opinion of management, all adjustments (consisting of normal accruals) considered for a fair presentation have been included. Significant estimates made in preparing these financial statements include (a) assumptions to calculate the fair values of financial instruments, warrants and equity instruments and other liabilities and the deferred tax asset valuation allowance and (b) the useful lives for depreciable and amortizable assets. Actual results could differ from those estimates. In the opinion of management, all adjustments, including normal recurring accruals considered necessary for a fair presentation, have been included.
Consolidation	Consolidation - The accompanying financial statements include the accounts of the Company and its wholly-owned subsidiary, GVR. All significant intercompany balances and transactions have been eliminated.
Cash and Cash Equivalents	Cash and Cash Equivalents —We consider all liquid instruments purchased with a maturity of three months or less to be cash equivalents.
Concentration of Credit Risk	Concentration of Credit Risk —We maintain bank accounts at one U.S. financial institution. The U.S. bank accounts are insured by the Federal Deposit Insurance Corporation (FDIC) for up to $250,000 per account owner. GVR, our wholly owned Swiss-based subsidiary maintains checking accounts at one major national financial institution. Additionally, we maintain a checking account with a very minimal balance at one bank in South Korea, which is used to fund payroll and rent in South Korea. Management believes we are not exposed to significant credit risk due to the financial position of the depository institutions in which our deposits are held.
Restricted Cash	Restricted Cash —Restricted cash at December 31, 2017 represented cash held within a certificate of deposit with a financial institution. The certificate of deposit served as collateral for our corporate credit card program, which was terminated in 2018. The restriction was lifted upon termination of the program. As of December 31, 2018 our restricted cash balance consists of a $211,000 pledged mutual fund account which is held as collateral against a letter of credit issued in May 2018 in connection with the lease of our corporate headquarters. Effective January 1, 2018, we adopted ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash , which requires that the statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Consequently, restricted cash is included in the beginning and ending cash balances on the statement of cash flows. See also Note 10- Commitments and Contingencies, for further details.
Investments	Investments —Securities held-to-maturity: Management determines the appropriate classification of debt securities at the time of purchase and reevaluates such designation as of each balance sheet date. Investment/debt securities are classified as held-to-maturity when we have the positive intent and ability to hold the securities to maturity. Held-to-maturity securities are stated at amortized cost, adjusted for amortization of premiums and accretion of discounts to maturity computed under the effective interest method. Such amortization is included in investment income. Interest on securities classified as held-to-maturity is included in interest and investment income. When the fair value of an investment instrument classified as held-to-maturity is less than its amortized cost, management assesses whether or not: (i) we have the intent to sell the instrument or (ii) it is more likely than not that we will be required to sell the instrument before its anticipated recovery. If either of these conditions is met, we must recognize an other-than-temporary impairment for the difference between the instrument’s amortized cost basis and its fair value, and include such amounts in other income (expense). For investment instruments that do not meet the above criteria and are not expected to be recovered at the amortized cost basis, the instrument is considered other-than-temporarily impaired. For these instruments, we separate the total impairment into the credit loss component and the amount of the loss related to other factors. In order to determine the amount of the credit loss, we calculate the recovery value by performing a discounted cash flow analysis based on the current cash flows and future cash flows management expects to recover. The discount rate is the effective interest rate implicit in the underlying instrument. The amount of the total other-than-temporary impairment related to credit loss is recognized in earnings and is included in other income (expense). The amount of the total other-than-temporary impairment related to other factors is recognized in other comprehensive income. For investment instruments that have other-than-temporary impairment recognized through earnings, if through subsequent evaluation there is a significant increase in the cash flow expected, the difference between the amortized cost basis and the cash flows expected to be collected is accreted as interest income.
Fair Value of Financial Instruments	Fair Value of Financial Instruments —We measure certain financial assets and liabilities at fair value based on the exchange price that would be received for an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants. The carrying amounts of our financial instruments, including cash equivalents, restricted cash, investments held-to-maturity, accounts payable, and accrued liabilities, approximate fair value due to their short maturities.
Accounts Receivable	Accounts Receivable —Trade accounts receivable are stated net of allowances for doubtful accounts. Management estimates the allowance for doubtful accounts based on review and analysis of specific customer balances that may not be collectible, customer payment history and any other customer-specific information that may impact collectability of the receivable. Accounts are considered for write-off when they become past due and when it is determined that the probability of collection is remote.
Property and Equipment	Property and Equipment —Property and equipment consists of leasehold improvements associated with our corporate offices, software purchased during the normal course of business, equipment and office furniture and fixtures, all of which are recorded at cost. Depreciation and amortization is recorded using the straight-line method over the respective useful lives of the assets ranging from three to five years . Leasehold improvements are amortized over the shorter of lease term or useful life. Long-lived assets are reviewed for impairment whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable.
Intangible Assets, net	Intangible Assets, net —Intangible assets are recorded at cost and amortized over the useful life. In the case of business combinations, intangible assets are recorded at fair value. At December 31, 2017 and December 31, 2018 , intangible assets, net, includes patents, domain name and other intangibles purchased from GVR, including customer relationships, technology and trademark. Intangible assets are reviewed for impairment whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable. In certain cases, patents may expire or are abandoned as we no longer plan to pursue them. In such cases we write off the capitalized patent costs as patent abandonment costs which are included in research and development expenses.
Goodwill	Goodwill— At December 31, 2017 and December 31, 2018 , goodwill represents the difference between the price paid to acquire GVR and the fair value of the assets acquired, net of assumed liabilities. We review goodwill for impairment annually and whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable.
Revenue Recognition	Revenue Recognition —As of January 1, 2018, we recognize revenue in accordance with Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, Topic 606, Revenue from Contracts with Customers. Revenue is recognized upon the transfer of control of promised goods or services to the customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. Revenue consists primarily of upfront non-refundable fees received in connection with filter design projects with customers and royalties. Our performance obligation is to design a licensable filter in accordance with customer specifications. The license of the completed design is considered part of this performance obligation as the design and licensing of the filter are highly interdependent. We recognize revenue over the course of the design development phase as our customers are able to benefit from our design services as they are provided, primarily by marketing the in-process design to their customers. We recognize revenue from our design services based on efforts expended to date. At the end of each reporting period, we reassess our measure of progress and adjust revenue when appropriate. In most cases, upfront non-refundable payments are recognized over a period of 12 to 18 months. Contracts generally include upfront non-refundable fees, intended to support our initial engineering product development efforts, and may include milestone payments based upon the successful completion of certain deliverables. Milestone payments represent variable consideration, and we use the "most likely amount" approach to determine the amount we ultimately expect to receive. At contract inception, we assess the likelihood of achieving milestones to estimate the total consideration we believe we will receive for our services. Our design service contracts also include a functional license over the completed design, which enables our customer to use our design in products marketed to their customers. We also earn royalties for each product shipped by our customer that incorporates one of our designs. Royalty fees are recorded upon shipment by our customer, and payment is generally due within 30 days. We record the expenses related to these projects in the periods incurred and they are generally included in research and development expense.
Research and Development	Research and Development —Costs and expenses that can be clearly identified as research and development are charged to expense as incurred in accordance with ASC Topic 730-10, Research and Development .
Operating Leases	Operating Leases —We lease office space and research facilities under operating leases. Certain lease agreements contain free or escalating rent payment provisions. We recognize rent expense under such leases on a straight-line basis over the term of the lease. Lease renewal periods are considered on a lease-by-lease basis in determining the lease term.
Stock-Based Compensation	Stock-Based Compensation —We account for employee stock options in accordance with ASC Topic 718, Compensation-Stock Compensation . For stock options issued to employees and directors we use the Black-Scholes option valuation model for estimating fair value at the date of grant. For stock options issued for services rendered by non-employees, we recognize compensation expense in accordance with the requirements of ASC Topic 505-50 , Equity , or ASC 505-50, as amended. Non-employee option grants that do not vest immediately upon grant are recorded as an expense over the vesting period. At the end of each financial reporting period prior to performance, the value of these options, as calculated using the Black-Scholes option valuation model, is determined, and compensation expense recognized or recovered during the period is adjusted accordingly. Since the fair market value of options granted to non-employees is subject to change in the future, the amount of the future compensation expense is subject to adjustment until the common stock options are fully vested. We account for restricted stock units issued to employees at fair value, based on the market price of our stock on the date of grant, net of estimated forfeitures. Compensation expense is recognized for the portion of the award that is ultimately expected to vest over the period during which the recipient renders the required services to the Company generally using the straight-line single option method. The fair value of non-employee restricted stock units awarded are remeasured as the awards vest, and the resulting increase or decrease in fair value, if any, is recognized as an increase or decrease to compensation expense in the period the related services are rendered. In the case of award modifications, we account for the modification in accordance with ASU No. 2017-09, Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting , whereby we recognize the effect of the modification in the period the award is modified. Stock-based compensation expense is included in research and development expenses and sales, marketing and administration expenses.
Earnings Per Share, or EPS	Earnings Per Share, or EPS —EPS is computed in accordance with ASC Topic 260, Earnings per Share , and is calculated using the weighted average number of common shares outstanding during each period. Diluted EPS assumes the conversion, exercise or issuance of all potential common stock equivalents unless the effect is to reduce a loss or increase the income per share. Potential common shares consist of the incremental common shares issuable upon the exercise of stock options (using the treasury stock method), the exercise of warrants (using the if-converted method) and the vesting of restricted stock unit awards.
Income Taxes	Income Taxes —We account for income taxes in accordance with ASC Topic 740, Income Taxes , or ASC 740, which requires the recognition of deferred tax assets and liabilities for the future consequences of events that have been recognized in our consolidated financial statements or tax returns. The measurement of the deferred items is based on enacted tax laws. In the event the future consequences of differences between financial reporting bases and the tax bases of our assets and liabilities result in a deferred tax asset, ASC 740 requires an evaluation of the probability of being able to realize the future benefits indicated by such asset. A valuation allowance related to a deferred tax asset is recorded when it is more likely than not that some portion or the entire deferred tax asset will not be realized. As part of the process of preparing our consolidated financial statements, we are required to estimate our income tax expense in each of the jurisdictions in which we operate. We also assess temporary differences resulting from differing treatment of items for tax and accounting differences. We record a valuation allowance to reduce the deferred tax assets to the amount of future tax benefit that is more likely than not to be realized. For the period when we were organized as a limited liability company, we were treated as a partnership for federal and state income tax purposes under the entity classification domestic default rules. As of December 31, 2017 and December 31, 2018 , no liability for unrecognized tax benefits was required to be reported. We recognize interest and penalties related to income tax matters in income taxes, and there were none for the years ended December 31, 2017 and December 31, 2018 , respectively. We have filed, or are in the process of filing, tax returns that are subject to audit by the respective tax authorities. Although the ultimate outcome is unknown, we believe that any adjustments that may result from tax return audits are not likely to have a material, adverse effect on our consolidated results of operations, financial position or cash flows.
Business Combinations	Business Combinations— We record business combinations using the acquisition method of accounting and, accordingly, allocate the fair value of purchase consideration to the assets acquired and liabilities assumed based on their fair values at the acquisition date. The excess of the fair value of the purchase consideration over the fair value of the assets acquired and liabilities assumed is recorded as goodwill. The results of operations of the business acquired are included in our consolidated results of operations beginning on the date of acquisition.
Foreign Currency Translation	Foreign Currency Translation —The Swiss Franc has been determined to be the functional currency for the net assets of our Swiss-based subsidiary. We translate the assets and liabilities to U.S. dollars at each reporting period using exchange rates in effect at the balance sheet date and record the effects of the foreign currency translation in accumulated other comprehensive income (loss) in shareholders' equity. We translate the income and expenses to U.S. dollars at each reporting period using the average exchange rate in effect for the period and record the effects of the foreign currency translation as other comprehensive income (loss) in the consolidated statements of comprehensive loss. Gains and losses resulting from foreign currency transactions are included in net loss in the consolidated statements of comprehensive loss.
Recent Accounting Pronouncements	Recent Accounting Pronouncements Leases— In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) , a comprehensive new leases standard that amends various aspects of existing accounting guidance for leases. It will require recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. The main difference between previous U.S. GAAP and the amended standard is the recognition of lease assets and lease liabilities by lessees on the balance sheet for those leases classified as operating leases under previous U.S. GAAP. The accounting applied by a lessor is largely unchanged from that applied under previous U.S. GAAP. As a result, we will have to recognize a liability to make lease payments (the lease liability) and a right-of-use asset representing our right to use the underlying asset for the lease term on the balance sheet. In July 2018, the FASB issued ASU 2018-10, Codification Improvements to Topic 842, Leases , which provides clarity to certain narrow aspects of the new standard and ASU 2018-11, Leases (Topic 842): Targeted Improvements , which provides an optional transition method for adopting the new leases guidance that eliminates comparative period reporting under the new guidance in the year of adoption. The guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted. We plan to adopt the standard, as well as the practical expedients included therein, utilizing the optional transition method as of January 1, 2019. Therefore, we will not restate comparative periods in our 2019 financial statements. We have reviewed our leases and other agreements in order to determine the effects of the new guidance on our consolidated financial statements. We have determined that we have two facility leases that meet the criteria for recognition of lease assets and lease liabilities on the balance sheet under the new guidance. We are not party to any leases for which we are the lessor. We believe the adoption will cause us to recognize approximately $3.0 million in each, right-of-use assets and lease liabilities, in our consolidated financial statements. Intangibles-Goodwill and Other— In January 2017, the FASB issued ASU No. 2017-04, Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment , which simplifies the accounting for goodwill impairments by eliminating step 2 from the goodwill impairment test. The amended guidance will become effective for us commencing in the first quarter of fiscal 2019. We plan to adopt the standard as of January 1, 2019 and we do not believe there will be any material impact to our consolidated financial statements. Compensation-Stock Compensation— In June 2018, the FASB issued ASU No. 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Non-employee Share-Based Payment Accounting , which intends to align the accounting of share-based payment awards issued to employees and non-employees. This update will be effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2018. Early adoption is permitted. We plan to adopt the standard as of January 1, 2019 and we do not believe there will be any material impact to our consolidated financial statements as we have very few share-based payment arrangements with non-employees.

REVENUE RECOGNITION (Tables)

REVENUE RECOGNITION (Tables)	12 Months Ended
	Dec. 31, 2018
Revenue from Contract with Customer [Abstract]
Schedule of New Accounting Pronouncements and Changes in Accounting Principles	The following table summarizes the impact of the adoption on our Consolidated Balance Sheet and Consolidated Statement of Comprehensive Loss as of and for the year ended December 31, 2018: BALANCE SHEET As of December 31, 2018 As Reported Balances Without Adoption of ASC 606 Effect of Change Increase/(Decrease) ASSETS Prepaid expenses and other current assets $ 364,000 $ 364,000 $ — LIABILITIES AND STOCKHOLDERS' EQUITY Deferred revenue, current $ 271,000 $ 264,000 $ 7,000 Accumulated deficit $ (92,564,000 ) $ (92,557,000 ) $ (7,000 ) STATEMENT OF COMPREHENSIVE LOSS Year Ended December 31, 2018 As Reported Activity Without Adoption of ASC 606 Effect of Change Increase/(Decrease) Revenue $ 524,000 $ 595,000 $ (71,000 ) Net loss $ (24,816,000 ) $ (24,745,000 ) $ 71,000 The cumulative effect of the changes made to our consolidated balance sheet as of January 1, 2018 for the adoption of the new standard was as follows: BALANCE SHEET Balance as of December 31, 2017 Adjustments Due to ASC 606 Balance as of January 1, 2018 ASSETS Prepaid expenses and other current assets $ 536,000 $ 67,000 $ 603,000 LIABILITIES AND STOCKHOLDERS' EQUITY Deferred revenue, current $ 143,000 $ 3,000 $ 146,000 Accumulated deficit $ (67,812,000 ) $ 64,000 $ (67,748,000 )
Contract with Customer, Asset and Liability	Summary of changes in contract assets and liabilities for the period from January 1, 2018 to December 31, 2018: Contract assets Contract assets, January 1, 2018 $ 67,000 Contract assets at beginning of year transferred to accounts receivable (43,000 ) Reversal of contract assets due to changes in transaction price (24,000 ) Contract assets recorded on contracts during the period 36,000 Contract assets, December 31, 2018 $ 36,000 Contract liabilities Contract liabilities, January 1, 2018 $ 146,000 Recognition of revenue included in beginning of year contract liabilities (138,000 ) Contract liabilities, net of revenue recognized on contracts during the period 263,000 Contract liabilities, December 31, 2018 $ 271,000
Disaggregation of Revenue	The following table presents our disaggregated revenue by geographic region and source: Year Ended December 31, 2017 2018 Revenue by geographic region: United States $ 574,000 $ 447,000 Switzerland 79,000 77,000 Total revenue $ 653,000 $ 524,000 Revenue by source: Design services $ 613,000 $ 365,000 Royalties 40,000 159,000 Total revenue $ 653,000 $ 524,000

PROPERTY AND EQUIPMENT, NET (Ta

PROPERTY AND EQUIPMENT, NET (Tables)	12 Months Ended
	Dec. 31, 2018
Property, Plant and Equipment [Abstract]
Schedule of property and equipment, net	Property and equipment, net, consists of the following: As of December 31, 2017 As of December 31, 2018 Cost: Computers, peripheral and scientific equipment $ 1,016,000 $ 1,350,000 Software 1,367,000 1,749,000 Leasehold improvements 502,000 294,000 Office furniture and equipment 327,000 391,000 3,212,000 3,784,000 Less: Accumulated depreciation and amortization (1,858,000 ) (1,797,000 ) Property and equipment, net $ 1,354,000 $ 1,987,000

INTANGIBLE ASSETS, NET, AND G_2

INTANGIBLE ASSETS, NET, AND GOODWILL (Tables)	12 Months Ended
	Dec. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets	Intangible assets, net, consists of the following: As of December 31, 2017 As of December 31, 2018 Cost: Patents $ 1,349,000 $ 1,507,000 Domain name 22,000 22,000 Client Base (1) 143,000 142,000 Trademark (1) 17,000 17,000 Backlog (1) 13,000 13,000 Technology 77,000 77,000 1,621,000 1,778,000 Less: Accumulated amortization (268,000 ) (404,000 ) Intangible assets, net $ 1,353,000 $ 1,374,000 (1) Includes the impact of foreign currency translation. The total impact at December 31, 2017 was $2,000 and the total impact at December 31, 2018 was $1,000 .
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	The following table summarizes the estimated amortization expense relating to the intangible assets as of December 31, 2018 : Years ending December 31, 2019 $ 112,000 2020 85,000 2021 76,000 2022 65,000 2023 63,000 2024 and thereafter 466,000 Total amortization expense $ 867,000
Schedule of Goodwill	The following table summarizes goodwill arising from the acquisition of GVR Trade: Goodwill Balance at January 1, 2017 $ 789,000 Effect of currency translation 35,000 Balance at December 31, 2017 $ 824,000 Effect of currency translation (7,000 ) Balance at December 31, 2018 $ 817,000

WARRANTS (Tables)

WARRANTS (Tables)	12 Months Ended
	Dec. 31, 2018
Warrants and Rights Note Disclosure [Abstract]
Schedule of warrant activity	A roll-forward of warrant activity from January 1, 2017 to December 31, 2017 is shown in the following table: Issued and Warrants Warrants Issued and Bridge Warrants 249,999 — — 249,999 Consulting Warrant 98,000 — (85,777 ) (1) 12,223 Financing Warrant 78,186 — (15,656 ) (2) 62,530 Underwriting Warrant 310,500 — — 310,500 IR Consulting Warrant 48,000 — (42,000 ) (3) 6,000 Private Placement Warrants - 2016 1,995,124 — (1,104,061 ) (4) 891,063 Underwriting Warrants - Public Offering 2016 135,750 — (13,575 ) (5) 122,175 Private Placement Warrants - February 2017 — 1,626,898 (1,626,898 ) (6) — Private Placement Warrants - September 2017 — 1,976,919 — 1,976,919 Placement Agent Warrants - 2017 — 98,846 — 98,846 2,915,559 3,702,663 (2,887,967 ) 3,730,255 (1) During the year ended December 31, 2017, there were 85,777 warrants that were exercised through cashless exercises, which netted 85,620 shares being issued. (2) During the year ended December 31, 2017, there were 15,656 warrants that were exercised through cashless exercises, which netted 6,842 shares being issued. (3) During the year ended December 31, 2017, 42,000 warrants expired. (4) During the year ended December 31, 2017, there were 122,281 warrants that were exercised through cashless exercises, which netted 49,063 shares being issued. Additionally, there were 981,780 warrants that were exercised for cash, which included 836,780 warrants exercised subject to inducement, which offered the warrant holder an inducement fee of $0.29 /share to exercise the warrant in full for cash immediately. (5) During the year ended December 31, 2017, there were 13,575 warrants that were exercised through cashless exercises, which netted 6,322 shares being issued. (6) During the year ended December 31, 2017, there were 1,626,898 warrants that were exercised for cash. The warrants were exercised subject to inducement, which offered the warrant holder an inducement fee of $4.13 /share to exercise the warrant in full for cash immediately. A roll-forward of warrant activity from January 1, 2018 to December 31, 2018 is shown in the following table: Exercise Price Expiration Date Issued and Warrants Issued and Bridge Warrants NA NA 249,999 (249,999 ) (1) — Consulting Warrant $0.01 6/17/2020 12,223 (5,556 ) (2) 6,667 Financing Warrant $3.35 6/17/2020 62,530 — 62,530 Underwriting Warrant $7.50 5/28/2019 310,500 — 310,500 IR Consulting Warrant NA NA 6,000 (6,000 ) (3) — Private Placement Warrants - 2016 $2.86 4/25/2019 891,063 (73,000 ) (4) 818,063 Underwriting Warrants - Public Offering 2016 $4.25 9/9/2019 122,175 — 122,175 Private Placement Warrants - September 2017 $4.85 9/28/2020 1,976,919 (10,600 ) (5) 1,966,319 Placement Agent Warrants - 2017 $4.85 9/28/2020 98,846 — 98,846 3,730,255 (345,155 ) 3,385,100 (1) During the year ended December 31, 2018, there were 249,999 warrants that were exchanged for 242,913 shares of common stock in an exchange transaction where the warrant holders exchanged the warrants for the same number of shares they would have been entitled to in a cashless exercise. (2) During the year ended December 31, 2018, there were 5,556 warrants that were exercised through a cashless exercise, which netted 5,542 shares being issued. (3) During the year ended December 31, 2018, 6,000 warrants expired. (4) During the year ended December 31, 2018, there were 73,000 warrants exercised for cash. (5) During the year ended December 31, 2018, there were 10,600 warrants exercised for cash.

STOCKHOLDERS' EQUITY (Tables)

STOCKHOLDERS' EQUITY (Tables)	12 Months Ended
	Dec. 31, 2018
Stockholders' Equity Note [Abstract]
Schedule of Repurchase Agreements	The following table presents the number of shares excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods below: Year Ended December 31, 2017 Year Ended December 31, 2018 Common stock warrants 3,730,255 3,385,100 Common stock options 1,082,490 1,255,280 Non-vested restricted stock unit awards 1,476,858 1,921,594 Total shares excluded from net loss per share attributable to common stockholders 6,289,603 6,561,974

STOCK-BASED COMPENSATION (Table

STOCK-BASED COMPENSATION (Tables)	12 Months Ended
	Dec. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of fair values of stock options granted, estimated using Black-Scholes option valuation model assumptions	The fair values of stock options granted for the years were estimated using the following assumptions: Option Grants Awarded During the Year Ended December 31, 2017 Option Grants Awarded During the Year Ended December 31, 2018 Stock Price $4.36 - $7.80 $1.80 - $5.96 Dividend Yield 0% 0% Expected Volatility 60.0% 70.0% Risk-free interest rate 1.95% - 2.37% 2.50% - 3.09% Expected Term 7 to 10 years 7 years
Summary of stock option activity	The following is a summary of our stock option activity during the year ended December 31, 2017 : Number of Options Weighted Average Exercise Price Weighted Average Grant Date Fair Value Weighted Average Remaining Life In Years Outstanding, January 1, 2017 801,690 $ 5.25 $ 3.32 7.40 Granted 488,300 4.62 2.79 9.51 Exercised (32,928 ) 2.37 1.41 — Canceled/Forfeited (174,572 ) 6.40 4.18 — Outstanding, December 31, 2017 1,082,490 $ 4.87 $ 3.00 8.38 Number of Options Weighted Average Exercise Price Weighted Average Grant Date Fair Value Weighted Average Remaining Life In Years Exercisable, January 1, 2017 419,174 $ 5.94 $ 3.86 6.00 Vested 457,338 4.57 2.77 8.65 Exercised (32,928 ) 2.37 1.41 — Canceled/Forfeited (139,281 ) 6.65 4.38 — Exercisable, December 31, 2017 704,303 $ 5.08 $ 3.17 8.15 The following is a summary of our stock option activity during the year ended December 31, 2018 : Number of Options Weighted Average Exercise Price Weighted Average Grant Date Fair Value Weighted Average Remaining Life In Years Outstanding, January 1, 2018 1,082,490 $ 4.87 $ 3.00 8.38 Granted 252,500 4.54 3.09 9.16 Exercised (4,692 ) 2.10 1.75 — Canceled/Forfeited (75,018 ) 4.72 2.89 — Outstanding, December 31, 2018 1,255,280 $ 4.82 $ 3.03 7.75 Number of Options Weighted Average Exercise Price Weighted Average Grant Date Fair Value Weighted Average Remaining Life In Years Exercisable, January 1, 2018 704,303 $ 5.08 $ 3.17 8.15 Vested 161,404 4.69 2.89 7.56 Exercised (4,692 ) 2.10 1.75 — Canceled/Forfeited (17,996 ) 4.72 2.84 — Exercisable, December 31, 2018 843,019 $ 5.02 $ 3.13 7.23
Schedule of information related to stock options outstanding and exercisable	The following table presents information related to stock options outstanding and exercisable at December 31, 2018 : Options Outstanding Options Exercisable Exercise Price Outstanding Number of Options Weighted Average Remaining Life In Years Exercisable Number of Options $1.80 - $2.00 161,183 7.09 99,637 $3.25 - $4.92 652,297 8.41 393,944 $5.01 - $6.00 281,500 5.87 214,115 $6.18 – $7.20 70,000 5.97 55,004 $7.54 – $7.80 67,800 6.09 58,749 $8.06 - $12.98 22,500 6.05 21,570 1,255,280 7.23 843,019
Schedule of Share-based Compensation, Restricted Stock Units Award Activity	A summary of restricted stock unit activity for the year ended December 31, 2017 is as follows: Number of Restricted Share Units Weighted-Average Grant-Date Fair Value Per Share Outstanding at January 1, 2017 1,455,558 $ 3.64 Granted 722,400 5.37 Vested (649,359 ) 4.26 Forfeited (51,741 ) 5.40 Outstanding at December 31, 2017 1,476,858 $ 4.96 A summary of restricted stock unit activity for the year ended December 31, 2018 is as follows: Number of Restricted Share Units Weighted-Average Grant-Date Fair Value Per Share Outstanding at January 1, 2018 1,476,858 $ 4.96 Granted 1,661,750 4.60 Vested (1,051,939 ) 4.68 Forfeited (165,075 ) 5.17 Outstanding at December 31, 2018 1,921,594 $ 4.78
Schedule of stock-based compensation	Total stock-based compensation recorded in the consolidated statements of comprehensive loss is allocated as follows: Year Ended Year Ended December 31, 2018 Research and development Employees $ 1,937,000 $ 2,479,000 Non-employees 181,000 77,000 Total research and development 2,118,000 2,556,000 Sales, marketing and administration Employees and directors 1,824,000 2,604,000 Non-employees 179,000 102,000 Total sales, marketing and administration 2,003,000 2,706,000 Total stock-based compensation $ 4,121,000 $ 5,262,000

COMMITMENT AND CONTINGENCIES (T

COMMITMENT AND CONTINGENCIES (Tables)	12 Months Ended
	Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Schedule of future minimum lease payments under operating leases	Future minimum rent payments are as follows: Years ending December 31, 2019 $ 658,000 2020 726,000 2021 748,000 2022 557,000 2023 555,000 2024 and thereafter 376,000 Total future minimum rent payments $ 3,620,000

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Schedule of income taxes by jurisdiction	The provision for (benefit from) income taxes by jurisdiction consists of the following: Year Ended December 31, 2017 Year Ended December 31, 2018 U.S. federal: Current $ — $ — Deferred — — Total U.S. federal — — U.S. state and local: Current 1,000 2,000 Deferred — — Total U.S. state and local 1,000 2,000 Foreign: Current — — Deferred (15,000 ) (1,000 ) Total foreign (15,000 ) (1,000 ) Provision for (benefit from) income taxes $ (14,000 ) $ 1,000
Schedule of income taxes differ from the amounts computed by applying the U.S. federal income tax rate to pretax income (loss) before income taxes	Income taxes differ from the amounts computed by applying the U.S. federal income tax rate to pretax income (loss) before income taxes as a result of the following: Year Ended December 31, 2017 Year Ended December 31, 2018 Expected income tax benefit $ (7,357,000 ) $ (5,211,000 ) State income tax (benefit), net of federal benefit (1,176,000 ) (1,997,000 ) Valuation allowance 7,398,000 7,372,000 Permanent differences: Stock options 95,000 285,000 Warrants 914,000 — Research & development credit (263,000 ) (405,000 ) Adjustment to deferred taxes 267,000 (68,000 ) Foreign rate differential 19,000 2,000 Other 89,000 23,000 Provision for (benefit from) for income taxes $ (14,000 ) $ 1,000
Schedule of components of deferred income tax	Deferred income tax consists of the following: As of December 31, 2017 As of December 31, 2018 U.S. federal and state deferred tax assets—long term: Accrued payroll $ 376,000 $ 102,000 Accrued expenses 21,000 45,000 Fixed assets 111,000 — Intangibles 457,000 418,000 Research & development credit 1,464,000 2,239,000 Net operating loss 13,204,000 20,140,000 Stock compensation 539,000 612,000 New jobs credit 8,000 8,000 Total long-term assets 16,180,000 23,564,000 Total deferred tax assets 16,180,000 23,564,000 U.S. federal and state deferred tax liabilities—long term: Fixed assets — (16,000 ) Total deferred tax liabilities — (16,000 ) Net deferred tax assets - long term 16,180,000 23,548,000 Less: Valuation allowance (16,180,000 ) (23,548,000 ) Net deferred tax assets $ — $ — Foreign deferred tax assets—long term: Net operating loss $ 12,000 $ 9,000 Total foreign deferred tax assets 12,000 9,000 Foreign deferred tax liabilities—long term: Intangibles (13,000 ) (4,000 ) Total foreign deferred tax liabilities (13,000 ) (4,000 ) Net foreign deferred tax assets (liabilities) (1,000 ) 5,000 Less: Valuation allowance — (5,000 ) Net deferred tax assets (liabilities) $ (1,000 ) $ —

ORGANIZATION AND DESCRIPTION _2

ORGANIZATION AND DESCRIPTION OF BUSINESS (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Jan. 01, 2018	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated deficit	$ (92,564)	$ (67,748)	$ (67,812)
Existing cash balances and investments	21,300
Cash used in operating activities	$ 19,600

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)	12 Months Ended
	Dec. 31, 2018USD ($)financial_institutionLease	Dec. 31, 2017USD ($)	Jan. 01, 2019USD ($)
Accounting Policies [Abstract]
Number of financial institutions | financial_institution	1
Restricted cash balance	$ 211,000
Income Taxes
Unrecognized tax benefits	0	$ 0
Income tax penalties and interest expense	$ 0	$ 0
Accounting Standards Update 2016-02
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Number of Leases | Lease	2
Subsequent Event | Forecast | Accounting Standards Update 2016-02
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Right-of-Use asset			$ 3,000,000
Operating lease liability			$ 3,000,000
Minimum
Property, Plant and Equipment [Line Items]
Useful lives	3 years
Maximum
Property, Plant and Equipment [Line Items]
Useful lives	5 years

REVENUE RECOGNITION (Schedule o

REVENUE RECOGNITION (Schedule of Effect of New Accounting Pronouncements) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Jan. 01, 2018
ASSETS
Prepaid expenses and other current assets	$ 364,000	$ 536,000	$ 603,000
LIABILITIES AND STOCKHOLDERS' EQUITY
Deferred revenue, current	271,000		146,000
Accumulated deficit	(92,564,000)	(67,812,000)	$ (67,748,000)
STATEMENT OF COMPREHENSIVE LOSS
Revenues	524,000	653,000
Net loss	(24,816,000)	(21,653,000)
Calculated under Revenue Guidance in Effect before Topic 606
ASSETS
Prepaid expenses and other current assets	364,000	536,000
LIABILITIES AND STOCKHOLDERS' EQUITY
Deferred revenue, current	264,000	143,000
Accumulated deficit	(92,557,000)	(67,812,000)
STATEMENT OF COMPREHENSIVE LOSS
Revenues	595,000
Net loss	(24,745,000)
Accounting Standards Update 2014-09 | Difference between Revenue Guidance in Effect before and after Topic 606
ASSETS
Prepaid expenses and other current assets	0	67,000
LIABILITIES AND STOCKHOLDERS' EQUITY
Deferred revenue, current	7,000	3,000
Accumulated deficit	(7,000)	$ 64,000
STATEMENT OF COMPREHENSIVE LOSS
Revenues	(71,000)
Net loss	$ 71,000

REVENUE RECOGNITION (Schedule_2

REVENUE RECOGNITION (Schedule of Changes in Contract Asset and Liability Balances) (Details)	12 Months Ended
	Dec. 31, 2018USD ($)
Contract assets
Contract assets, January 1, 2018	$ 67,000
Contract assets at beginning of year transferred to accounts receivable	(43,000)
Reversal of contract assets due to changes in transaction price	(24,000)
Contract assets recorded on contracts during the period	36,000
Contract assets, December 31, 2018	36,000
Contract liabilities
Contract liabilities, January 1, 2018	146,000
Recognition of revenue included in beginning of year contract liabilities	(138,000)
Contract liabilities, net of revenue recognized on contracts during the period	263,000
Contract liabilities, December 31, 2018	$ 271,000

REVENUE RECOGNITION (Schedule_3

REVENUE RECOGNITION (Schedule of Revenue from Customer by Geographic Area and Source) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Disaggregation of Revenue [Line Items]
REVENUES	$ 524,000	$ 653,000
United States
Disaggregation of Revenue [Line Items]
REVENUES	447,000	574,000
Switzerland
Disaggregation of Revenue [Line Items]
REVENUES	77,000	79,000
Design Services
Disaggregation of Revenue [Line Items]
REVENUES	365,000	613,000
Royalties
Disaggregation of Revenue [Line Items]
REVENUES	$ 159,000	$ 40,000

INVESTMENTS HELD-TO-MATURITY (D

INVESTMENTS HELD-TO-MATURITY (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Schedule of Held-to-maturity Securities [Line Items]
Amortized cost	$ 16,900,000
Fair value	16,900,000
Unrealized Gain (Loss)	0
Investments held-to-maturity	16,863,000	$ 0
Interest and investment income	$ 481,000	67,000
US Treasury Bills, Maturing April 2018 | Commercial Paper
Schedule of Held-to-maturity Securities [Line Items]
Investments held-to-maturity		25,000,000
Commercial Paper, Maturing In 2018 | Commercial Paper
Schedule of Held-to-maturity Securities [Line Items]
Investments held-to-maturity		14,600,000
Commercial Paper, Maturing January 2019 | Commercial Paper
Schedule of Held-to-maturity Securities [Line Items]
Investments held-to-maturity		16,900,000
Certificates of Deposit | Debt Securities
Schedule of Held-to-maturity Securities [Line Items]
Investments held-to-maturity		$ 100,000

PROPERTY AND EQUIPMENT, NET (De

PROPERTY AND EQUIPMENT, NET (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Property and equipment, gross	$ 3,784	$ 3,212
Less: Accumulated depreciation and amortization	(1,797)	(1,858)
PROPERTY AND EQUIPMENT, NET	1,987	1,354
Depreciation	704	595
Property disposed of	773	21
Computers, peripheral and scientific equipment
Property and equipment, gross	1,350	1,016
Software
Property and equipment, gross	1,749	1,367
Leasehold improvements
Property and equipment, gross	294	502
Office furniture and equipment
Property and equipment, gross	$ 391	$ 327

INTANGIBLE ASSETS, NET, AND G_3

INTANGIBLE ASSETS, NET, AND GOODWILL (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Finite-Lived Intangible Assets [Line Items]
Write-off of abandoned patents	$ 96	$ 8
Amortization of intangible assets	$ 136	$ 126
Patents | Minimum
Finite-Lived Intangible Assets [Line Items]
Useful life	17 years
Patents | Maximum
Finite-Lived Intangible Assets [Line Items]
Useful life	20 years
STI | Patents | Minimum
Finite-Lived Intangible Assets [Line Items]
Useful life	1 year
STI | Patents | Maximum
Finite-Lived Intangible Assets [Line Items]
Useful life	11 years
STI | Domain name
Finite-Lived Intangible Assets [Line Items]
Useful life	10 years
GVR Trade S.A. | Patents | Minimum
Finite-Lived Intangible Assets [Line Items]
Useful life	3 years
GVR Trade S.A. | Patents | Maximum
Finite-Lived Intangible Assets [Line Items]
Useful life	5 years

INTANGIBLE ASSETS, NET, AND G_4

INTANGIBLE ASSETS, NET, AND GOODWILL (Intangible Assets) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Finite-Lived Intangible Assets, Net [Abstract]
Intangible Assets, Gross	$ 1,778	$ 1,621
Less: Accumulated amortization	(404)	(268)
Net intangible assets	1,374	1,353
Impact of foreign currency translation	1	2
Patents
Finite-Lived Intangible Assets, Net [Abstract]
Intangible Assets, Gross	1,507	1,349
Domain name
Finite-Lived Intangible Assets, Net [Abstract]
Intangible Assets, Gross	22	22
Client Base
Finite-Lived Intangible Assets, Net [Abstract]
Intangible Assets, Gross	142	143
Trademark
Finite-Lived Intangible Assets, Net [Abstract]
Intangible Assets, Gross	17	17
Backlog
Finite-Lived Intangible Assets, Net [Abstract]
Intangible Assets, Gross	13	13
Technology
Finite-Lived Intangible Assets, Net [Abstract]
Intangible Assets, Gross	$ 77	$ 77

INTANGIBLE ASSETS, NET, AND G_5

INTANGIBLE ASSETS, NET, AND GOODWILL (Schedule of Future Amortization Expense) (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Finite-Lived Intangible Assets [Line Items]
Net intangible assets	$ 1,374	$ 1,353
Intangible Assets, Excluding Pending Patents
Finite-Lived Intangible Assets [Line Items]
2019	112
2020	85
2021	76
2022	65
2023	63
2024 and thereafter	466
Net intangible assets	$ 867

INTANGIBLE ASSETS, NET, AND G_6

INTANGIBLE ASSETS, NET, AND GOODWILL (Goodwill) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Goodwill [Roll Forward]
Balance at the beginning of the period	$ 824	$ 789
Effect of currency translation	(7)	35
Balance at the end of the period	$ 817	$ 824

WARRANTS (Narrative) (Details)

WARRANTS (Narrative) (Details)

Dec. 31, 2017USD ($)$ / sharesshares

Dec. 19, 2017USD ($)$ / sharesshares

Dec. 18, 2017USD ($)$ / shares

Sep. 28, 2017USD ($)$ / sharesshares

Apr. 25, 2016$ / sharesshares

Jun. 17, 2013$ / sharesshares

Dec. 31, 2017USD ($)$ / sharesshares

Sep. 30, 2017USD ($)$ / shares

Feb. 28, 2017USD ($)$ / sharesshares

Sep. 30, 2016$ / sharesshares

Apr. 30, 2016shares

Oct. 31, 2014$ / sharesshares

Aug. 31, 2014$ / sharesshares

Mar. 31, 2013$ / sharesshares

Jan. 31, 2013tranchefounder$ / sharesshares

Oct. 31, 2017$ / sharesshares

Mar. 31, 2013USD ($)$ / sharesshares

Sep. 30, 2016USD ($)$ / sharesshares

Dec. 31, 2018USD ($)$ / sharesshares

Dec. 31, 2017USD ($)$ / sharesshares

Dec. 31, 2016USD ($)

Oct. 02, 2017shares

Mar. 19, 2013shares

Warrant liabilities

Proceeds from exercises of warrants | $

$ 260,000

$ 9,272,000

Common stock issued | $

$ 20,000

$ 20,000

27,000

20,000

Non-cash warrant inducement expense | $

0

2,688,000

Sale of common stock, net of offering costs | $

21,189,000

15,950,000

Common Stock

Warrant liabilities

Sale of common stock, net of offering costs | $

$ 6,000

$ 4,000

Assumptions used in estimating fair value of warrants

Sales of common stock, net of offering costs (in shares) | shares

6,571,428

3,603,817

Exercise of warrants, cashless (in shares) | shares

147,847

Founders | Class B Member’s | Resonant LLC

Warrant liabilities

Warrants to purchase shares of common stock or units (in shares) | shares

124,998

Placement agents

Assumptions used in estimating fair value of warrants

Equity value | $

$ 200,000

Implied unit price/stock price (in dollars per share)

$ 4.85

Placement agents | Common Stock

Assumptions used in estimating fair value of warrants

Period end after closing

2 years

Placement agents | Private Placement, Offering One

Assumptions used in estimating fair value of warrants

Sold in private placement (in shares) | shares

87,279

Placement agents | Private Placement, Offering Two

Assumptions used in estimating fair value of warrants

Sold in private placement (in shares) | shares

11,567

Bridge Warrants | Resonant LLC

Warrant liabilities

Number of tranches in which warrants were issued | tranche

2

Proceeds from exercises of warrants | $

$ 1,000

Bridge Warrants | Founders

Warrant liabilities

Warrant term

5 years

5 years

Exercise price (in dollars per share)

$ 0.20

$ 0.4

$ 0.4

Warrants to purchase shares of common stock or units (in shares) | shares

249,999

Common stock issued | $

$ 1,600,000

Assumptions used in estimating fair value of warrants

Warrants and Rights outstanding, value | $

$ 1,600,000

Bridge warrants issued in January 2013

Warrant liabilities

Warrants to purchase shares of common stock or units (in shares) | shares

20,833

20,833

20,833

Bridge warrants issued in January 2013 | Class B Member’s | Resonant LLC

Warrant liabilities

Warrants to purchase shares of common stock or units (in shares) | shares

62,499

62,499

Consulting Warrant

Warrant liabilities

Exercise price (in dollars per share)

$ 0.01

Assumptions used in estimating fair value of warrants

Exercise of warrants, cashless (in shares) | shares

242,913

85,620

Consulting warrants issued in October 2014 | IR Consultant

Warrant liabilities

Warrant term

4 years

Exercise price (in dollars per share)

$ 6.50

Warrants to purchase shares of common stock or units (in shares) | shares

6,000

Financing Warrants

Warrant liabilities

Exercise price (in dollars per share)

$ 3.35

Assumptions used in estimating fair value of warrants

Exercise of warrants, cashless (in shares) | shares

5,542

6,842

Private Placement Warrants

Warrant liabilities

Exercise price (in dollars per share)

$ 2.86

Proceeds from exercises of warrants | $

2,200,000

Non-cash warrant inducement expense | $

239,000

Sale of common stock, net of offering costs | $

$ 2,400,000

Assumptions used in estimating fair value of warrants

Equity value | $

$ 2,500,000

Implied unit price/stock price (in dollars per share)

$ 2.90

$ 2.90

Expected volatility (as a percent)

60.00%

Expected dividend rate (as a percent)

0.00%

Risk free interest rate (as a percent)

0.97%

Expected Life

3 years

Exercise of warrants, cashless (in shares) | shares

49,063

Private Placement Warrants | Private Placement

Warrant liabilities

Warrants to purchase shares of common stock or units (in shares) | shares

836,780

836,780

1,996,880

836,780

Private Placement Warrants | Common Stock

Warrant liabilities

Fair value adjustment of warrants | $

$ 166,000

Inducement expense after fair value adjustment | $

$ 73,000

Assumptions used in estimating fair value of warrants

Equity value | $

$ 3,800,000

$ 3,900,000

Expected volatility (as a percent)

60.00%

10.00%

Expected dividend rate (as a percent)

0.00%

Risk free interest rate (as a percent)

2.00%

Expected Life

1 day

1 year 5 months 1 day

Private Placement Warrants | Minimum | Common Stock

Assumptions used in estimating fair value of warrants

Exercise price (in dollars per share)

$ 6.96

$ 6.96

$ 6.96

Risk free interest rate (as a percent)

1.00%

2.00%

Private Placement Warrants | Maximum | Common Stock

Assumptions used in estimating fair value of warrants

Exercise price (in dollars per share)

$ 7.42

$ 7.42

7.42

Risk free interest rate (as a percent)

1.00%

2.00%

Private Placement Warrants | Investors, Executives and Board Members

Warrant liabilities

Exercise price (in dollars per share)

$ 2.86

$ 2.86

$ 2.86

$ 2.86

Assumptions used in estimating fair value of warrants

Period start after closing

6 months

Period end after closing

36 months

Private Placement Warrants | Investors, Executives and Board Members | Private Placement

Assumptions used in estimating fair value of warrants

Sales of common stock, net of offering costs (in shares) | shares

1,996,880

Private Placement Warrants | Placement agents

Assumptions used in estimating fair value of warrants

Implied unit price/stock price (in dollars per share)

$ 2.86

Sales of common stock, net of offering costs (in shares) | shares

99,844

836,780

Underwriting Warrant

Warrant liabilities

Exercise price (in dollars per share)

7.50

Assumptions used in estimating fair value of warrants

Expected volatility (as a percent)

60.00%

Sales of common stock, net of offering costs (in shares) | shares

1,976,919

Underwriting Warrant | Common Stock

Warrant liabilities

Warrants to purchase shares of common stock or units (in shares) | shares

2,715,000

2,715,000

Assumptions used in estimating fair value of warrants

Equity value | $

$ 475,000

Implied unit price/stock price (in dollars per share)

$ 6.54

$ 6.54

Expected volatility (as a percent)

60.00%

Risk free interest rate (as a percent)

0.90%

Expected Life

3 years

Underwriting Warrant | Minimum

Assumptions used in estimating fair value of warrants

Implied unit price/stock price (in dollars per share)

$ 4.49

Risk free interest rate (as a percent)

1.59%

Underwriting Warrant | Maximum

Assumptions used in estimating fair value of warrants

Implied unit price/stock price (in dollars per share)

$ 4.69

Risk free interest rate (as a percent)

1.63%

Underwriting Warrant | Investors, Executives and Board Members

Warrant liabilities

Exercise price (in dollars per share)

$ 4.25

$ 4.25

Underwriting Warrant | Investors, Executives and Board Members | Private Placement

Assumptions used in estimating fair value of warrants

Sales of common stock, net of offering costs (in shares) | shares

135,750

Underwriting Warrant | Placement agents

Assumptions used in estimating fair value of warrants

Sales of common stock, net of offering costs (in shares) | shares

98,846

Private Placement Warrants - February 2017

Warrant liabilities

Proceeds from exercises of warrants | $

$ 6,700,000

Fair value adjustment of warrants | $

4,100,000

Non-cash warrant inducement expense | $

6,700,000

Inducement expense after fair value adjustment | $

2,600,000

Assumptions used in estimating fair value of warrants

Equity value | $

$ 13,400,000

$ 4,100,000

Implied unit price/stock price (in dollars per share)

$ 8.18

$ 8.18

Expected volatility (as a percent)

10.00%

Risk free interest rate (as a percent)

1.25%

Expected Life

1 year 8 months 1 day

Private Placement Warrants - February 2017 | Private Placement

Warrant liabilities

Warrants to purchase shares of common stock or units (in shares) | shares

1,626,898

1,626,898

Assumptions used in estimating fair value of warrants

Period end after closing

30 months

Private Placement Warrants - February 2017 | Investors, Executives and Board Members

Warrant liabilities

Exercise price (in dollars per share)

$ 8.25

Private Placement Warrants - February 2017 | Investors, Executives and Board Members | Common Stock

Warrant liabilities

Exercise price (in dollars per share)

$ 8.25

Private Placement Warrants - February 2017 | Individual Investor | Private Placement

Assumptions used in estimating fair value of warrants

Sales of common stock, net of offering costs (in shares) | shares

1,626,898

Private Placement Warrants - February 2017 | Individual Investor | Private Placement | Capital Units

Assumptions used in estimating fair value of warrants

Sales of common stock, net of offering costs (in shares) | shares

1,626,898

Private Placement Warrants, February 2017, After Modifications

Assumptions used in estimating fair value of warrants

Equity value | $

$ 6,700,000

Private Placement Warrants - September 2017

Warrant liabilities

Exercise price (in dollars per share)

$ 4.85

Assumptions used in estimating fair value of warrants

Equity value | $

$ 3,600,000

Private Placement Warrants - September 2017 | Private Placement

Warrant liabilities

Warrants to purchase shares of common stock or units (in shares) | shares

1,745,581

1,976,919

231,338

Assumptions used in estimating fair value of warrants

Period start after closing

6 months

Private Placement Warrants - September 2017 | Minimum

Assumptions used in estimating fair value of warrants

Implied unit price/stock price (in dollars per share)

$ 4.49

Risk free interest rate (as a percent)

1.59%

Private Placement Warrants - September 2017 | Maximum

Assumptions used in estimating fair value of warrants

Implied unit price/stock price (in dollars per share)

$ 4.69

Risk free interest rate (as a percent)

1.63%

Private Placement Warrants - September 2017 | Investors, Executives and Board Members | Capital Units

Warrant liabilities

Exercise price (in dollars per share)

$ 4.85

Private Placement Warrants - September 2017 | Investors, Executives and Board Members | Private Placement | Capital Units

Assumptions used in estimating fair value of warrants

Sales of common stock, net of offering costs (in shares) | shares

1,976,919

MDB | Consulting Warrant

Warrant liabilities

Warrant term

7 years

Exercise price (in dollars per share)

$ 0.01

Warrants to purchase shares of common stock or units (in shares) | shares

222,222

MDB | Financing Warrants

Warrant liabilities

Warrant term

7 years

Exercise price (in dollars per share)

$ 3.35

Warrants to purchase shares of common stock or units (in shares) | shares

208,763

MDB | Underwriting Warrant

Warrant liabilities

Warrant term

5 years

Exercise price (in dollars per share)

$ 7.50

Warrants to purchase shares of common stock or units (in shares) | shares

310,500

Assumptions used in estimating fair value of warrants

Warrants exercisable period from underwriting agreement

180 days

IR Firm | Consulting warrants issued in August 2014

Warrant liabilities

Number of founders | founder

3

Warrant term

3 years

Exercise price (in dollars per share)

$ 0.40

Warrants to purchase shares of common stock or units (in shares) | shares

42,000

Assumptions used in estimating fair value of warrants

Exercise price (in dollars per share)

$ 8.31

IR Firm | Private Placement Warrants - February 2017

Assumptions used in estimating fair value of warrants

Equity value | $

$ 2,100,000

Implied unit price/stock price (in dollars per share)

$ 4.91

Risk free interest rate (as a percent)

1.50%

Expected Life

3 years

Sales, marketing and administration | Bridge Warrants | Founders

Warrant liabilities

Fair value adjustment of warrants | $

$ 2,000

WARRANTS (Schedule of Warrant A

WARRANTS (Schedule of Warrant Activity) (Details) - $ / shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Roll forward of warrant activity
Balance at the beginning of the period (in shares)	3,730,255	2,915,559
Warrants Issued (in shares)		3,702,663
Warrant Exercised/Expired (in shares)	(345,155)	(2,887,967)
Balance at the end of the period (in shares)	3,385,100	3,730,255
Bridge Warrants
Roll forward of warrant activity
Balance at the beginning of the period (in shares)	249,999	249,999
Warrant Exercised/Expired (in shares)	(249,999)
Balance at the end of the period (in shares)	0	249,999
Consulting Warrant
Warrant liabilities
Exercise price (in dollars per share)	$ 0.01
Roll forward of warrant activity
Balance at the beginning of the period (in shares)	12,223	98,000
Warrant Exercised/Expired (in shares)	(5,556)	(85,777)
Balance at the end of the period (in shares)	6,667	12,223
Exercise of warrants, cashless (in shares)	242,913	85,620
Financing Warrants
Warrant liabilities
Exercise price (in dollars per share)	$ 3.35
Roll forward of warrant activity
Balance at the beginning of the period (in shares)	62,530	78,186
Warrant Exercised/Expired (in shares)	0	(15,656)
Balance at the end of the period (in shares)	62,530	62,530
Exercise of warrants, cashless (in shares)	5,542	6,842
Financing Warrants | Cashless
Roll forward of warrant activity
Warrant Exercised/Expired (in shares)	(5,556)	(15,656)
Underwriting Warrant
Warrant liabilities
Exercise price (in dollars per share)	$ 7.50
Roll forward of warrant activity
Balance at the beginning of the period (in shares)	310,500	310,500
Warrant Exercised/Expired (in shares)	0
Balance at the end of the period (in shares)	310,500	310,500
IR Consulting Warrants
Roll forward of warrant activity
Balance at the beginning of the period (in shares)	6,000	48,000
Warrant Exercised/Expired (in shares)	(6,000)	(42,000)
Balance at the end of the period (in shares)	0	6,000
Private Placement Warrants - 2016
Warrant liabilities
Exercise price (in dollars per share)	$ 2.86
Roll forward of warrant activity
Balance at the beginning of the period (in shares)	891,063	1,995,124
Warrants Issued (in shares)		0
Warrant Exercised/Expired (in shares)	(73,000)	(1,104,061)
Balance at the end of the period (in shares)	818,063	891,063
Exercise of warrants, cashless (in shares)		49,063
Private Placement Warrants - 2016 | Cashless
Roll forward of warrant activity
Warrant Exercised/Expired (in shares)	(73,000)	(122,281)
Private Placement Warrants - 2016 | Cash
Roll forward of warrant activity
Warrant Exercised/Expired (in shares)		(981,780)
Warrant exercised, subject to inducement (in shares)		836,780
Inducement, fee amount (in dollars per share)		$ 0.29
Underwriting Warrants - Public Offering 2016
Roll forward of warrant activity
Balance at the beginning of the period (in shares)	122,175	135,750
Warrants Issued (in shares)		0
Warrant Exercised/Expired (in shares)		(13,575)
Balance at the end of the period (in shares)		122,175
Private Placement Warrants - February 2017
Roll forward of warrant activity
Balance at the beginning of the period (in shares)	0	0
Warrants Issued (in shares)		1,626,898
Warrant Exercised/Expired (in shares)		(1,626,898)
Balance at the end of the period (in shares)		0
Private Placement Warrants - February 2017 | Cash
Roll forward of warrant activity
Warrant Exercised/Expired (in shares)		(1,626,898)
Inducement, fee amount (in dollars per share)		$ 4.13
Underwriting Warrants - Public Offering 2016
Warrant liabilities
Exercise price (in dollars per share)	$ 4.25
Roll forward of warrant activity
Balance at the beginning of the period (in shares)	122,175
Warrant Exercised/Expired (in shares)		(13,575)
Balance at the end of the period (in shares)	122,175	122,175
Exercise of warrants, cashless (in shares)		6,322
Private Placement Warrants - September 2017
Warrant liabilities
Exercise price (in dollars per share)	$ 4.85
Roll forward of warrant activity
Balance at the beginning of the period (in shares)	1,976,919	0
Warrants Issued (in shares)		1,976,919
Warrant Exercised/Expired (in shares)	(10,600)	0
Balance at the end of the period (in shares)	1,966,319	1,976,919
Placement Agent Warrants - 2017
Warrant liabilities
Exercise price (in dollars per share)	$ 4.85
Roll forward of warrant activity
Balance at the beginning of the period (in shares)	98,846	0
Warrants Issued (in shares)		98,846
Warrant Exercised/Expired (in shares)	0
Balance at the end of the period (in shares)	98,846	98,846

STOCKHOLDERS' EQUITY (Details)

STOCKHOLDERS' EQUITY (Details) - USD ($)	Apr. 06, 2018	Mar. 27, 2018	Oct. 02, 2017	Sep. 28, 2017	Feb. 22, 2017	Apr. 25, 2016	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Nov. 26, 2018	Dec. 31, 2016	Sep. 30, 2016
Class of Stock [Line Items]
Common stock, shares authorized (in shares)							47,000,000	47,000,000	47,000,000
Class of warrant or right, outstanding							3,730,255	3,385,100	3,730,255		2,915,559
Net proceeds from the sale of common stock from private placement offerings								$ 0	$ 15,950,000
Legal Fees					$ 29,000
Sale of common stock, net of offering costs								$ 21,189,000	$ 15,950,000
Preferred stock, shares authorized (in shares)							3,000,000	3,000,000	3,000,000
Stock Repurchase Program [Abstract]
Authorized repurchase amount										$ 4,000,000
Repurchase and retirement of common stock								$ 152,000
Repurchase and retirement of common stock, average price per share (in dollars per share)								$ 1.88
Shares excluded from computation of earnings per share (in shares)								6,561,974	6,289,603
Placement agents
Class of Stock [Line Items]
Share price (in dollars per share)				$ 4.85
Capital Units | Institutional and Individual Investors
Class of Stock [Line Items]
Share price (in dollars per share)			$ 4.85	4.70	$ 4.61
Capital Units | Placement agents
Class of Stock [Line Items]
Share price (in dollars per share)				$ 4.85
Common stock warrants
Class of Stock [Line Items]
Class of warrant or right, outstanding			1		1
Stock Repurchase Program [Abstract]
Shares excluded from computation of earnings per share (in shares)								3,385,100	3,730,255
Common stock warrants | Institutional and Individual Investors
Class of Stock [Line Items]
Period start after closing				6 months	6 months
Period end after closing				36 months	30 months
Common Stock
Class of Stock [Line Items]
Sales of common stock, net of offering costs (in shares)		5,714,286	1		1
Share price (in dollars per share)		$ 3.50			$ 8.25
Net proceeds from the sale of common stock from private placement offerings		$ 20,000,000
Sale of common stock, net of offering costs		$ 18,400,000
Stock Repurchase Program [Abstract]
Repurchase and retirement of common stock (in shares)								(80,100)
Shares excluded from computation of earnings per share (in shares)								1,255,280	1,082,490
Restricted stock units
Stock Repurchase Program [Abstract]
Shares excluded from computation of earnings per share (in shares)								1,921,594	1,476,858
Private Placement, Offering Two | Placement agents
Class of Stock [Line Items]
Sold in private placement (in shares)				11,567
Private Placement, Offering Two | Capital Units | Institutional and Individual Investors
Class of Stock [Line Items]
Net proceeds from the sale of common stock from private placement offerings			$ 1,100,000	$ 8,200,000	$ 7,500,000
Proceeds from issuance of private placement, net of offering costs			$ 1,000,000	$ 7,500,000
Sold in private placement (in shares)			231,338
Private Placement, Offering Two | Common stock warrants | Placement agents
Class of Stock [Line Items]
Sold in private placement (in shares)			98,846
Over-Allotment Option | Common Stock
Class of Stock [Line Items]
Sales of common stock, net of offering costs (in shares)	857,142
Share price (in dollars per share)	$ 3.50
Net proceeds from the sale of common stock from private placement offerings	$ 3,000,000
Sale of common stock, net of offering costs	$ 2,800,000
Private Placement Warrants
Class of Stock [Line Items]
Share price (in dollars per share)												$ 2.90
Class of warrant or right, outstanding							891,063	818,063	891,063		1,995,124
Sale of common stock, net of offering costs							$ 2,400,000
Private Placement Warrants | Placement agents
Class of Stock [Line Items]
Sales of common stock, net of offering costs (in shares)						99,844	836,780
Share price (in dollars per share)						$ 2.86
Private Placement Warrants | Private Placement | Capital Units | Institutional and Individual Investors
Class of Stock [Line Items]
Sales of common stock, net of offering costs (in shares)			1,976,919	1,745,581	1,626,898

STOCK-BASED COMPENSATION (Narra

STOCK-BASED COMPENSATION (Narrative) (Details) $ / shares in Units, $ in Thousands

Sep. 30, 2019

Aug. 08, 2016

Jun. 30, 2017shares

Jan. 31, 2017shares

Aug. 31, 2016shares

Jun. 30, 2016shares

Dec. 31, 2018USD ($)item$ / sharesshares

Dec. 31, 2017USD ($)$ / sharesshares

Dec. 31, 2015

Mar. 27, 2018$ / shares

Feb. 22, 2017$ / shares

Dec. 31, 2014shares

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Weighted Average Remaining Life In Years

7 years 2 months 23 days

8 years 1 month 24 days

6 years

Granted (in shares) | shares

252,500

488,300

Grant date fair value | $

$ 779

$ 1,400

Unrecognized compensation expense related to unvested employee stock option | $

$ 6,300

Compensation cost not yet recognized, period for recognition

2 years 1 month 13 days

Number of shares vested in the period | shares

161,404

457,338

Number of grants in the period, weighted average exercise price | $ / shares

$ 4.54

$ 4.62

Non-vested restricted stock unit awards

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Weighted Average Remaining Life In Years

7 years 2 months 23 days

Granted (in shares) | shares

252,500

488,300

Number of quarter over which awards vest from grant date subsequent to initial vesting | item

16

Stock compensation expense | $

$ 469

$ 435

Unrecognized compensation expense related to unvested employee stock option | $

$ 1,100

Options outstanding, aggregate intrinsic value | $

2,900

Options vested, aggregate intrinsic value | $

$ 1,700

Share price (in dollars per share) | $ / shares

$ 1.33

$ 7.47

Expected Volatility

70.00%

60.00%

Non-vested restricted stock unit awards | Minimum

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share price (in dollars per share) | $ / shares

$ 1.80

$ 1.93

Risk-free interest rate

2.50%

1.30%

Expected Life

7 years

7 years

Non-vested restricted stock unit awards | Maximum

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share price (in dollars per share) | $ / shares

$ 6

$ 5.5

Dividend Yield

0.00%

0.00%

Risk-free interest rate

3.09%

2.06%

Expected Life

7 years

7 years

Restricted stock units

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Granted (in dollars per share) | $ / shares

$ 4.60

$ 5.37

Stock compensation expense | $

$ 4,800

$ 3,600

Granted (in shares) | shares

1,661,750

722,400

Vested (in shares) | shares

(1,051,939)

(649,359)

Number of shares forfeited in period | shares

165,075

51,741

Restricted stock units | Minimum

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Vesting period

3 years

Restricted stock units | Maximum

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Vesting period

4 years

2014 Omnibus Incentive Plan

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of shares of common stock approved for issuance | shares

5,950,000

1,400,000

Reserved for future issuance | shares

1,189,389

Number of additional shares authorized | shares

3,250,000

1,300,000

2014 Omnibus Incentive Plan | Non-vested restricted stock unit awards

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Term of award

10 years

10 years

2014 Omnibus Incentive Plan | Non-vested restricted stock unit awards | Minimum

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Exercise price range, lower limit (in dollars per share) | $ / shares

$ 1.80

$ 4.36

2014 Omnibus Incentive Plan | Non-vested restricted stock unit awards | Maximum

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Exercise price range, upper limit (in dollars per share) | $ / shares

$ 5.96

$ 7.8

Employees | Non-vested restricted stock unit awards

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Forfeitures rate

6.00%

Employees | Restricted stock units

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Vesting period

10 days

Consultants

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Weighted Average Remaining Life In Years

10 years

Consultants | Non-vested restricted stock unit awards

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock compensation expense | $

$ 7

$ 9

Executive employees | Non-vested restricted stock unit awards

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Accelerated vesting, number (in shares) | shares

8,752

Option exercise period extended, number (in shares) | shares

17,504

Plan modification, incremental compensation cost | $

0

19

Executive employees | Performance Based Awards

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Award vesting rights, percentage

50.00%

Granted (in shares) | shares

250,000

Executive employees | Performance Based Awards | Maximum | Forecast

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Award vesting rights, percentage

50.00%

Common Stock

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share price (in dollars per share) | $ / shares

$ 3.50

$ 8.25

Common Stock | Executive employees | 2015 Performance Plan | Performance Based Awards

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Fair value of award | $

74

Stock compensation expense | $

$ 24

Compensation cost not yet recognized | $

$ 18

Vesting period

9 months

STOCK-BASED COMPENSATION (Estim

STOCK-BASED COMPENSATION (Estimated Fair Value of Stock Options) (Details) - Non-vested restricted stock unit awards - $ / shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share price (in dollars per share)	$ 1.33	$ 7.47
Expected Volatility	70.00%	60.00%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share price (in dollars per share)	$ 1.80	$ 1.93
Risk-free interest rate	2.50%	1.30%
Expected Life	7 years	7 years
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share price (in dollars per share)	$ 6	$ 5.5
Dividend Yield	0.00%	0.00%
Risk-free interest rate	3.09%	2.06%
Expected Life	7 years	7 years

STOCK-BASED COMPENSATION (Stock

STOCK-BASED COMPENSATION (Stock Option Award Activity) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2015
Number of Options outstanding
Outstanding at the beginning of the year (in shares)	1,082,490	801,690
Granted (in shares)	252,500	488,300
Exercised (in shares)	(4,692)
Forfeited (in shares)	(75,018)	(174,572)
Outstanding at the end of the reporting period (in shares)	1,255,280	1,082,490
Number of Options Exercisable
Exercisable at the beginning of the year (in shares)	704,303	419,174
Vested (in shares)	(161,404)	(457,338)
Forfeited (in shares)	(17,996)	(139,281)
Exercisable at the end of the reporting period (in shares)	843,019	704,303
Weighted Average Exercise Price Outstanding
Outstanding at the beginning of period (in dollars per share)	$ 4.87	$ 5.25
Granted (in dollars per share)	4.54	4.62
Exercised (in dollars per share)	2.10
Forfeited (in dollars per share)	4.72	6.40
Outstanding at the end of the reporting period (in dollars per share)	4.82	4.87
Weighted Average Exercise Price Exercisable
Exercisable at the beginning of the reporting period (in dollars per share)	5.08	5.94
Vested exercisable (in dollars per share)	4.69	4.57
Canceled/Forfeited (in dollars per share)	4.72	6.65
Exercisable at the end of the reporting period (in dollars per share)	5.02	5.08
Weighted Average Grant Date Fair Value Outstanding
Outstanding at the beginning of the reporting period (in dollars per share)	3	3.32
Options granted (in dollars per share)	3.09	2.79
Exercised (in dollars per share)	1.75
Forfeited (in dollars per share)	2.89	4.18
Outstanding at the end of the reporting period (in dollars per share)	3.03	3
Weighted Average Grant Date Fair Value Exercisable
Exercisable at the beginning of the reporting period (in dollars per share)	3.17	3.86
Vested options exercisable (in dollars per share)	$ 2.89	2.77
Exercised (in dollars per share)	$ 1.75
Forfeited options exercisable (in dollars per share)	$ 2.84	4.38
Exercisable at the end of the reporting period (in dollars per share)	$ 3.13	$ 3.17
Weighted Average Remaining Life In Years Outstanding
Outstanding at the end of the reporting period (in years)	7 years 9 months	8 years 4 months 17 days	7 years 4 months 24 days
Granted, Weighted average remaining life (in years)	9 years 1 month 28 days	9 years 6 months 4 days
Weighted Average Remaining Life Exercisable
Exercisable at the end of the reporting period (in years)	7 years 2 months 23 days	8 years 1 month 24 days	6 years
Vested, Weighted average remaining live (in years)	7 years 6 months 22 days	8 years 7 months 24 days
Non-vested restricted stock unit awards
Number of Options outstanding
Granted (in shares)	252,500	488,300
Exercised (in shares)		(32,928)
Outstanding at the end of the reporting period (in shares)	1,255,280
Number of Options Exercisable
Exercisable at the end of the reporting period (in shares)	843,019
Weighted Average Exercise Price Outstanding
Exercised (in dollars per share)		$ 2.37
Weighted Average Grant Date Fair Value Outstanding
Exercised (in dollars per share)		$ 1.41
Weighted Average Remaining Life Exercisable
Exercisable at the end of the reporting period (in years)	7 years 2 months 23 days

STOCK-BASED COMPENSATION (Sto_2

STOCK-BASED COMPENSATION (Stock Options Outstanding and Exercisable) (Details) - $ / shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2015	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding Number of Options	1,255,280	1,082,490		801,690
Weighted Average Remaining Life In Years	7 years 2 months 23 days	8 years 1 month 24 days	6 years
Exercisable Number of Options	843,019	704,303		419,174
Non-vested restricted stock unit awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding Number of Options	1,255,280
Weighted Average Remaining Life In Years	7 years 2 months 23 days
Exercisable Number of Options	843,019
Non-vested restricted stock unit awards | $1.80 - $2.00
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding Number of Options	161,183
Weighted Average Remaining Life In Years	7 years 1 month 2 days
Exercisable Number of Options	99,637
Non-vested restricted stock unit awards | $3.25 - $4.92
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding Number of Options	652,297
Weighted Average Remaining Life In Years	8 years 4 months 28 days
Exercisable Number of Options	393,944
Non-vested restricted stock unit awards | $5.01 - $6.00
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding Number of Options	281,500
Weighted Average Remaining Life In Years	5 years 10 months 13 days
Exercisable Number of Options	214,115
Non-vested restricted stock unit awards | $6.18 – $7.20
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding Number of Options	70,000
Weighted Average Remaining Life In Years	5 years 11 months 19 days
Exercisable Number of Options	55,004
Non-vested restricted stock unit awards | $7.54 – $7.80
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding Number of Options	67,800
Weighted Average Remaining Life In Years	6 years 1 month 2 days
Exercisable Number of Options	58,749
Non-vested restricted stock unit awards | $8.06 - $12.98
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding Number of Options	22,500
Weighted Average Remaining Life In Years	6 years 18 days
Exercisable Number of Options	21,570
Non-vested restricted stock unit awards | Minimum | $1.80 - $2.00
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Range	$ 1.93
Non-vested restricted stock unit awards | Minimum | $3.25 - $4.92
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Range	3.83
Non-vested restricted stock unit awards | Minimum | $5.01 - $6.00
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Range	5.06
Non-vested restricted stock unit awards | Minimum | $6.18 – $7.20
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Range	6.18
Non-vested restricted stock unit awards | Minimum | $7.54 – $7.80
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Range	7.54
Non-vested restricted stock unit awards | Minimum | $8.06 - $12.98
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Range	8.06
Non-vested restricted stock unit awards | Maximum | $1.80 - $2.00
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Range	2
Non-vested restricted stock unit awards | Maximum | $3.25 - $4.92
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Range	4.70
Non-vested restricted stock unit awards | Maximum | $5.01 - $6.00
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Range	6
Non-vested restricted stock unit awards | Maximum | $6.18 – $7.20
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Range	7.20
Non-vested restricted stock unit awards | Maximum | $7.54 – $7.80
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Range	7.80
Non-vested restricted stock unit awards | Maximum | $8.06 - $12.98
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Range	$ 12.98

STOCK-BASED COMPENSATION (Restr

STOCK-BASED COMPENSATION (Restricted Stock Activity) (Details) - Restricted stock units - $ / shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Restricted Share Units
Outstanding at beginning of year (in shares)	1,476,858	1,455,558
Granted (in shares)	1,661,750	722,400
Vested (in shares)	(1,051,939)	(649,359)
Canceled (in shares)	(165,075)	(51,741)
Outstanding at end of year (in shares)	1,921,594	1,476,858
Restricted Share Weighted Average Grant Date Fair Value
Outstanding at beginning of year (in dollars per share)	$ 4.96	$ 3.64
Granted (in dollars per share)	4.60	5.37
Vested (in dollars per share)	4.68	4.26
Canceled (in dollars per share)	5.17	5.40
Outstanding at end of year (in dollars per share)	$ 4.78	$ 4.96

STOCK-BASED COMPENSATION (Equit

STOCK-BASED COMPENSATION (Equity Based Compensation Schedule) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Allocation of stock-based compensation expense
Stock compensation expense	$ 5,262	$ 4,121
Research and development
Allocation of stock-based compensation expense
Stock compensation expense	2,556	2,118
Research and development | Employees
Allocation of stock-based compensation expense
Stock compensation expense	2,479	1,937
Research and development | Non-employees
Allocation of stock-based compensation expense
Stock compensation expense	77	181
Sales, marketing and administration
Allocation of stock-based compensation expense
Stock compensation expense	2,706	2,003
Sales, marketing and administration | Non-employees
Allocation of stock-based compensation expense
Stock compensation expense	102	179
Sales, marketing and administration | Employees and directors
Allocation of stock-based compensation expense
Stock compensation expense	$ 2,604	$ 1,824

COMMITMENT AND CONTINGENCIES (N

COMMITMENT AND CONTINGENCIES (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Operating Leases
Purchase commitment amount	$ 193,000
Restricted cash balance	211,000
Loss contingency accrual	0	$ 0
Loss in period	0	$ 0
Corporate Headquarters
Operating Leases
Security deposit	50,000
Restricted cash balance	211,000
Letter of Credit | Corporate Headquarters
Operating Leases
Line of Credit Facility, Maximum Borrowing Capacity	200,000
Line of Credit Facility, Annual Step Down of No Defaults	$ 50,000

COMMITMENT AND CONTINGENCIES (F

COMMITMENT AND CONTINGENCIES (Future Minimum Lease Payments) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Rent expense	$ 663,000	$ 477,000
Future minimum lease payments
2019	658,000
2020	726,000
2021	748,000
2022	557,000
2023	555,000
2024 and thereafter	376,000
Total minimum rent payments	$ 3,620,000

INCOME TAXES (Income Taxes by J

INCOME TAXES (Income Taxes by Jurisdiction) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
U.S. federal:
Current	$ 0	$ 0
Deferred	0	0
Total U.S. federal	0	0
U.S. state and local:
Current	2,000	1,000
Deferred	0	0
Total U.S. state and local	2,000	1,000
Foreign:
Current	0	0
Deferred	(1,000)	(15,000)
Total foreign	1,000	15,000
Income taxes differ from the amounts computed by applying the U.S. federal income tax rate to pretax income (loss) before income taxes
Expected income tax benefit	(5,211,000)	(7,357,000)
State income tax (benefit), net of federal benefit	(1,997,000)	(1,176,000)
Valuation allowance	7,372,000	7,398,000
Permanent differences:
Stock options	285,000	95,000
Warrants	0	914,000
Research & development credit	(405,000)	(263,000)
Adjustment to deferred taxes	(68,000)	267,000
Foreign rate differential	2,000	19,000
Other	23,000	89,000
Provision for (benefit from) income taxes	$ 1,000	$ (14,000)

INCOME TAXES (Deferred Tax Asse

INCOME TAXES (Deferred Tax Assets and Liabilities) (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
U.S. federal and state deferred tax liabilities—long term:
Net deferred tax assets (liabilities)	$ 0	$ (1,000)
U.S. Federal and State
U.S. federal and state deferred tax assets—long term:
Accrued payroll	102,000	376,000
Accrued expenses	45,000	21,000
Fixed assets	0	111,000
Intangibles	418,000	457,000
Research & development credit	2,239,000	1,464,000
Net operating loss	20,140,000	13,204,000
Stock compensation	612,000	539,000
New jobs credit	8,000	8,000
Total long-term assets	23,564,000	16,180,000
Total deferred tax assets	23,564,000	16,180,000
U.S. federal and state deferred tax liabilities—long term:
Fixed assets	(16,000)	0
Net deferred tax assets - long term	23,548,000	16,180,000
Less: Valuation allowance	(23,548,000)	(16,180,000)
Net deferred tax assets	0	0
Net operating loss	20,140,000	13,204,000
Foreign
U.S. federal and state deferred tax assets—long term:
Net operating loss	9,000	12,000
U.S. federal and state deferred tax liabilities—long term:
Less: Valuation allowance	(5,000)	0
Net deferred tax assets	5,000
Net operating loss	9,000	12,000
Intangibles	$ (4,000)	(13,000)
Net deferred tax assets (liabilities)		$ (1,000)

INCOME TAXES (Narrative) (Detai

INCOME TAXES (Narrative) (Details) - USD ($)	1 Months Ended	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017
Operating Loss Carryforwards [Line Items]
Provision for (benefit from) income taxes		$ (1,000)	$ 14,000
State and Local Income Tax Expense (Benefit), Continuing Operations		2,000	1,000
Foreign income tax expense		(1,000)	(15,000)
Tax Cuts and Jobs Act of 2017, Change in tax rate, income tax expense (benefit)	$ 6,100,000
Increase of valuation allowance		7,400,000	1,300,000
Federal net operating loss carryforwards		71,600,000
State net operating loss carryforwards		72,900,000
Tax Cuts and Jobs Act of 2017, Federal Net Operating Loss Carryforwards		24.9
Interest
Penalties		0	0
Significant uncertain tax positions	$ 0	0	$ 0
Switzerland
Operating Loss Carryforwards [Line Items]
Net operating loss		61,000
Engineering Design and Fabrication Advisory Services | Director
Operating Loss Carryforwards [Line Items]
Expenses from transaction with related party		$ 26,000

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details) - Engineering Design and Fabrication Advisory Services - Director - USD ($)	12 Months Ended
	Dec. 31, 2018	Aug. 31, 2016
Related Party Transactions
Due to related party, advisory services agreement		$ 120,000
Expenses from transaction with related party	$ 26,000

EMPLOYEE BENEFIT PLAN (Details)

EMPLOYEE BENEFIT PLAN (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
401(k) Savings Retirement Plan
Recorded plan matching contributions	$ 372	$ 284

Uncategorized Items - resn-2018

Label	Element	Value
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	$ 64,000
Restricted Cash, Current	us-gaap_RestrictedCashCurrent	100,000
Restricted Cash, Current	us-gaap_RestrictedCashCurrent	211,000
Retained Earnings [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	$ 64,000